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Abstract 
Bacterial resistance to antibiotics is one of the most serious problems facing medicine today.  
Recently, reports have appeared describing bacteria that are resistant to daptomycin (dap), an important 
antibiotic used against systemic infections caused by various Gram-positive (Gram+) bacteria, 
including methicillin-resistant Staphylococcus aureus (MRSA).  This has caused considerable concern 
amongst the medical community. With few medicines being developed to replace them, research on 
antibiotics of last resort is imperative. 
Dap is a branched, cyclic lipodepsipeptide consisting of a 10-amino acid macrolactone ring to which 
is attached an exocyclic tripeptide bearing a decanoyl acyl tail.  Its activity is calcium-dependent. The 
action mode best substantiated involves the killing of bacteria through specific interaction with 
phosphatidylglycerol (PG) in their cell membranes, followed by the formation of oligomeric, cation-
selective pores and dissipation of membrane potential. The successive steps of the action mode have 
been investigated using fluorescence-based assays in model membranes. The steps include, 1) calcium-
mediated binding of monomers to PG at the outer leaflet; 2) formation of oligomers; 3) formation of 
pores through equilibration and alignment of oligomers across both membrane leaflets. The assay 
fluorophores include the intrinsically fluorescent kynurenine residue in dap, and various 
environmentally sensitive labels attached to dap by chemical modification.  
The objective of this work was to investigate three topics: the means by which lysyl-
phosphatidylglycerol (LPG) disrupts the action mode of dap, the means through which dap induces 
toxicity in humans, and the characterization of synthetic dap analogs, including an acyl-linked dimer. 
LPG is of interest because its increased formation is a known resistance mechanism for many cationic 
antimicrobial peptides (CAMPs); it is also correlated to resistance to dap specifically. A potential 
component in dap-induced toxicity is presence of phosphatidylserine (PS) in mammalian tissues. PS is 
a major phospholipid, and was investigated due to its anionic properties, which may emulate bacterial 
PG. The characterization of synthetic dap analogs allows for the study of the structure-activity 
relationship (SAR) of dap. The LPG, PS and characterization studies were pursued using the 
aforementioned fluorescence assays on a model membrane system using large unilamellar vesicles 
(LUV; liposomes), and antibacterial activity assays as needed. LUVs may be substituted with Bacillus 
subtilis L-forms (cell wall deficient bacteria) when necessary. Deviations in the assay results on LPG 
liposomes give insight into the action mode step(s) impeded in LPG-mediated bacterial resistance. The 
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success or failure of the assays on PS membranes gives insight into the mechanism of toxicity via 
potential PS-mediated dap binding and permeabilization of mammalian cells. Characterization of the 
SAR of dap may lead to potential pharmacological improvements. Understanding these topics may also 
result in lipopeptides with improved activity on dap-resistant bacteria, modifications to the established 
mechanism of action, and suggestions for further investigations into dap toxicity.   
In parallel and in combination with these experiments, it was investigated whether secondary 
interactions between peptidoglycan precursors and dap are of importance in its action mode; the 
macromolecular synthesis of the cell wall has long been suspected to play a part in the mechanism of 
action of dap, either through inhibition of peptidoglycan synthesis or binding of teichoic acids. The 
investigation was pursued using minimum inhibitory concentration (MIC) tests on B. subtilis L-forms. 
The MIC tests incorporate two antibiotics: one being dap, and the other to up- or down-regulate the 
abundance of a peptidoglycan precursor. B. subtilis L-forms are capable of growth in the absence of 
peptidoglycan, therefore its presence as a model organism is essential. The regulation of the abundance 
of the peptidoglycan precursors should increase or decrease the MIC of dap depending on its reliance 
on that precursor. Understanding the reliance of dap on cellular binding sites, may result in lipopeptides 
with improved activity on dap-resistant bacteria and modifications to the established mechanism of 
action. 
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Chapter 1 
Introduction: antibiotics, daptomycin and L-forms 
Since 1977, the World Health Organization (WHO) has maintained the Model List of Essential 
Medicines.1–3 Essential medicines were first defined as “of utmost importance, basic, indispensable, 
and necessary for the health and needs of the population.”1–3 A year later at the Alma Ata conference, 
the provision of essential medicines was declared one of the eight elements of primary health care.2,3 
The list has been updated on average every 2 years; the most recently released is, as of now, the 19th 
edition in April of 2015. The medicines are selected by criteria of disease relevance, evidence of 
efficacy and safety, and cost-effectiveness.2–4 Since its inception, the list has included a multitude of 
antibiotics, which are our main defense against bacterial infections. Nonetheless, the problem of 
antibacterial resistance has been increasing. 
The list of essential medicines now contains antibiotics of last resort for “the treatment of life-
threatening hospital-based infection due to suspected or proven multidrug-resistant infection.”4 These 
include medicines such as vancomycin and imipenem. Clinical bacterial isolates resistant to 
vancomycin, and imipenem, have already long been discovered.5,6 In May 2015, the World Health 
Assembly endorsed the WHO’s global action plan on antimicrobial resistance7. The WHO calls to 
“strengthen knowledge through surveillance and research” and to “optimize the use of antimicrobial 
agents.”7 
In 2003, the FDA approved daptomycin (dap; section 1.2), the most recent antibiotic belonging to a 
new class of antibacterials. Dap soon became a powerful antibiotic against the multi-drug resistant 
“superbug” methicillin-resistant Staphylococcus aureus (MRSA). Unfortunately, resistance has already 
been seen in clinical bacterial isolates subjected to dap.8,9 With few medicines being developed to 
replace them, research on these antibiotics of last resort is imperative. This thesis will investigate 
various aspects of dap, this includes: the means by which lysyl-phosphatidylglycerol (LPG) disrupts its 
action mode, whether phosphatidylserine (PS) is related to dap-induced toxicity in humans, the 
characterization of synthetic dap analogs to further the structure-activity relationship (SAR) of dap 
residues, and its reliance on peptidoglycan precursors in its mode of action. 
1.1 The history of antibiotics 
Antibiotics were first developed in the early 20th century. Paul Ehrlich had been devoted to early anti-
trypanosome (eukaryotic human parasite) chemicals, but had begun work with bacteria by 1907.10,11 
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Ehrlich asserted substances may act as a “magic bullet” and eliminate pathogenic bacteria through a 
selective affinity for their cells.10,11 By 1909, his group had discovered Salvarsan (arsphenamine), an 
anti-syphilis drug, through large-scale drug screening.11 Salvarsan and its modifications remained the 
standard treatment for syphilis until the first sulfonamide (sulfa) drug, Prontosil rubrum, was developed 
in the mid-1930s.10,11 Sulfa drugs dominated the market until the work of Alexander Fleming, which 
was underway in the late 1920s, came to fruition in the 1940s with the release of penicillin G.11,12 
Penicillin G (benzylpenicillin) was the first antibiotic in the penicillin class, which is itself a class within 
the broader family of β-lactam antibiotics. 
The discovery of these initial drugs, and the pressures of the Second World War, led to an antibiotic 
era now called the “Golden Age”.13,14 The discoveries of this era are summarized by Silver13 in a 
timeline spanning over a hundred years (Figure 1.1). The most abundant discoveries were made in the 
1940s through to the 1960s; the years following 1987 are characterized by a “discovery void”.  
 
Figure 1.1: The progress of antibacterial development. Each antibiotic represents a new drug class at the 
date of their initial discoveries.13 
During the discovery void, new antibiotics have come to market.  However, in all cases this has been 
due to class modifications rather than novel discoveries; the general antibiotic class of these drugs had 
already been discovered.13 This includes dap, which came to market in 2003, but whose class was first 
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reported in 1987 and resides at the edge of the discovery void.13,15 The decline in novel discoveries 
results from a decrease in research from large pharmaceutical companies, highly profitable 
improvements from class modification, and higher screening costs.13 In regards to screening costs, 
Baltz16 recounts the difficulties encountered by GlaxoSmithKline researchers in screening chemical 
libraries against multiple potential Gram-positive (Gram+) or broad spectrum targets. 
Over 300 genes were evaluated, and 160 were found to be essential 
for viability. They screened against 67 target proteins covering a wide 
range of cellular metabolic activities, and 16 yielded hits, but only 5 
yielded leads... Of these, peptide deformylase, FabH, and FabI are 
proven targets for antibiotics produced by actinomycetes or fungi, 
leaving only two (3%) as potentially new targets. The authors noted 
that: ‘The level of success was unsustainably low in relation to the 
large effort invested’ 
In spite of the lack of new antibiotic classes during the discovery void, the widespread use of 
antibacterials has continued to decrease morbidity and mortality from infectious diseases.17 Some 
have predicted that this trend will reverse as resistance to antibiotics increases, eventually giving rise 
to a “post-antibiotic era”.17 Ehrlich saw early evidence of resistance in his work with trypanosomes: 
the red dye fuchsin lost trypanocidal activity after prolonged application.10 Salvarsan, his first 
antibacterial drug, did not initially encounter the same difficulties. However, Prontosil and the other 
sulfa drugs have since seen widespread resistance.11 Penicillin G suffered the same outcome; within a 
few years of its introduction, fifty percent of Staphylococcus aureus bacteria were no longer 
susceptible.17 As the development of antibiotics has progressed, so has resistance. Across the world 
multidrug-resistant bacteria, or “super bugs”, have been found in clinical isolates. It is now 
acknowledged that it is simply a matter of time before bacterial resistance threatens new antibiotics. 
1.1.1 Action modes of select antibiotics 
Antibiotics have a wide variety of action modes. However, they usually fall within four broad classes, 
three of which consist in the inhibition of enzymes involved in: (1) peptidoglycan synthesis (2) protein 
synthesis and (3) nucleic acid synthesis, regulation, or repair. Common enzyme targets include 
transpeptidases, transglycosylases, topoisomerases, RNA polymerase and peptidyl transferases. The 
fourth mechanism involves disruption of the bacterial cell membrane. Below, antibiotics in three of the 
four classes will be discussed. The examples are limited, but relevant, to the research discussed 
throughout this thesis. For an overview, refer to Table 1.1. 
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Inhibitors of peptidoglycan synthesis 
The contents of Gram+ bacteria are enclosed by a system composed of a cell membrane and cell wall 
(Figure 1.2).  Gram-negative (Gram−) bacteria have developed a more complex system, which includes 
an additional outer membrane. In both, the cell membrane(s) consists of lipids, and the cell wall is made 
of peptidoglycan. 
 
Figure 1.2: Cell wall and membrane structure of Gram+ and Gram− bacteria, and mycobacteria. LPS: 
lipopolysaccharide, LTA: lipoteichoic acid, MDR: multi-drug resistance (efflux) system.18 
Peptidoglycan, also called murein, is a highly organized and peptide cross-linked carbohydrate 
polymer. Its synthesis occurs through several successive enzyme-catalyzed steps (Figure 1.3). The 
backbone is composed of alternating β-1,4-linked N-acetylglucosamine (GlcNAc) and N-
acetylmuramic acid (MurNAc) carbohydrate units. The peptide cross-links contain varying L- or D-
amino acids; alanine (Ala), lysine (Lys) and glycine (Gly) are often present.  
The biosynthetic enzymes of peptidoglycan provide high specific activity against bacteria within 
mammalian tissues, as they are absent from eukaryotic cells. However, in these environments the rigid 
peptidoglycan layer is required to prevent osmotic lysis; the bacterial cytosol is of higher osmotic 
activity than mammalian tissues, resulting in the influx of water and high osmotic pressure.19 
Consequently, the loss or weakening of the integrity of the peptidoglycan layer within mammalian 
tissue by the action modes of antibiotics can cause osmotic lysis of the bacterial cells. 
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Figure 1.3: Simplified biosynthesis of peptidoglycan: (I) Phosphoenolpyruvate (PEP) supplies a lactate 
residue (Lac) to GlcNAc, yielding MurNAc [UDP-GlcNAc-enolpyruvyltransferase; murA (1)]. (II) A 
pentapeptide containing a terminal D-Ala dipeptide is built onto MurNAc [L-Ala racemase (2) and Ala 
ligase (3)]. (III) The building block is transferred to undecaprenol phosphate, yielding lipid I [phosphor-
MurNAc-pentapeptide translocase; mraY (4)]. (IV) The building block is extended with GlcNAc and 
glycine, yielding lipid II, and flipped across the membrane [lipid II flippase (5)]. (V) Lipid II is transferred 
to a growing strand with a transglycosylase (6). (VI) The final transpeptidase reaction (7) crosslinks the 
strands. Light gray: cell membrane, UDP: uridine diphosphate.18 
Fosfomycin. The first step of peptidoglycan synthesis (Figure 1.3 I) involves PEP providing lactate 
to form MurNAc from GlcNAc; murA catalyzes the reaction20–22. The antibiotic fosfomycin, is an 
antimetabolite of murA (Figure 1.4). Uptake of the antibiotic is mediated by the glycerophosphate 
transporter. Fosfomycin inactivates murA through a reaction between its epoxide ring and an active site 
cysteine residue in the enzyme, which produces a stable thioether.21  Inactivation of murA leads to a 
depletion in a main substrate required for peptidoglycan synthesis. The result is a loss of the 
peptidoglycan layer. Fosfomycin is used clinically for treatment of urinary tract infections.23 
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Figure 1.4: Fosfomycin, PEP, and glycerophosphate structures. Uptake of fosfomycin and PEP are 
mediated by the glycerophosphate transporter. Fosfomycin inactivates the active site murA, the enzyme 
required for addition of Lac to GlnNAc, preventing MurNAc synthesis and thus peptidoglycan synthesis. 
Cycloserine. Following production of the MurNAc substrate, a pentapeptide is synthesized to form 
UDP-MurNAc-pentapeptide (Figure 1.3 II). The pentapeptide is important for peptidoglycan strand 
cross-linking. The C-terminus of the mature peptide is formed by two D-Ala residues. The D-Ala 
monomers are produced and linked by two enzymes: alanine racemase and alanine ligase, respectively. 
Alanine racemase converts L-Ala to D-Ala; D-alanine ligase is an ATP-dependent enzyme which 
catalyzes the formation of the peptide bond between the two residues. The dipeptide is then attached as 
a unit.24 The antibiotic cycloserine, a structural analogue of Ala, is an antimetabolite of both enzymes 
(Figure 1.5). Cycloserine uptake is mediated by the same transport system as D-Ala, L- Ala, and Gly in 
B. subtilis.25 Inhibition of the enzymes is said to occur through competitive inhibition.24,26 However, 
evidence has shown that inhibition of D-alanine ligase may occur in a different manner.27 Inhibition of 
the enzymes leads to a decrease in the intracellular production of lipid I and lipid II. The result is the 
loss of the peptidoglycan layer. Cycloserine is used clinically for treatment of tuberculosis and is on 
the WHO’s list of essential medicines.4 
 
Figure 1.5: Cycloserine inhibits the two enzymes which successively produce the D-alanyl-D-alanine 
dipeptide used in the producion of the precursors to lipid I. The first enzyme is alanine racemase, and the 
second is D-alanine ligase. Cycloserine works as it is a structural analogue of Ala (structures shown). 
Laspartomycin. The initial synthesis of peptidoglycan occurs on the inner face of the cytoplasmic 
membrane with the production of UDP-MurNac-pentapeptide, as described above. This precursor is 
then transferred to the carrier lipid undecaprenol phosphate, yielding lipid I (Figure 1.3 III). Addition 
of GlcNAc to lipid I yields lipid II, which is subsequently flipped across the membrane. Laspartomycin, 
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and some other lipopeptides like amphomycin, sequester the bare undecaprenol phosphate in the 
membrane.28,29  This interaction blocks the production of membrane-bound peptidoglycan precursors, 
and results in the loss of the peptidoglycan layer. Lapartomycin is an interesting antibiotic as it has 
structural similarity to dap and belongs to the same acidic lipopeptide antibiotic class, but they have 
different modes of action (see section 1.2.2). Laspartomycin is not used clinically. 
Ampicillin. Peptidoglycan synthesis concludes with the cross-linking of the peptidoglycan strands on 
the extracellular side of the cell membrane (Figure 1.3 VI). This is essential for the mechanical strength 
of the cell wall. Cross-linking occurs through muramyl-transpeptidase activity performed by the 
penicillin-binding proteins (PBPs). The β-lactam antibiotics inhibit the transpeptidase reaction through 
an irreversible covalent bond with the catalytic serine residue in the muramyl-transpeptidase active site 
(Figure 1.6).18 Ampicillin belongs to the β-lactam class. The mechanism of action, and name of the 
class, arises from a shared β-lactam ring which resembles the peptide bond of the D-alanyl-D-alanine 
dipeptide in the pentapeptide. Irreversible inhibition of the enzymes leads to a decrease in 
peptidoglycan cross-linking. The result is the loss of the peptidoglycan structural integrity. Ampicillin 
is used clinically as a broad-spectrum antibiotic, and is on the WHO’s list of essential medicines.4 
 
Figure 1.6: Deactivation of peptidoglycan transpeptidases by ampicillin occurs through covalent bond 
formation with the active site serine residue.  Bond formation occurs due to the resemblance of the ultimate 
lipid II dipeptide to the β-lactam group within ampicillin. 
Vancomycin. The concluding step of peptidoglycan synthesis is also inhibited by vancomycin; 
however, contrary to the β-lactam antibiotics, the antibiotic interacts with the substrate of the 
transpeptidase reaction, rather than the enzyme itself. Vancomycin sequesters the D-alanyl-D-alanine 
dipeptide by interacting through five essential hydrogen bonds (Figure 1.7).30 Sequestration of the 
substrate blocks the active site serine from interacting with the pentapeptide. As with ampicillin, 
vancomycin leads to a decrease in peptidoglycan cross-linking. The result is the loss of the 
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peptidoglycan structural integrity. Vancomycin is used clinically against a range of infections, 
including MRSA, and is on the WHO’s list of essential medicines.4,31 
 
Figure 1.7: Sequestration of D-alanyl-D-alanine dipeptide by vancomycin.  Sequestration occurs through 
five essential hydrogen bonds and blocks the cross-linking of peptidoglycan by PBPs. Black: vancomycin, 
blue: terminal D-alanyl-D-alanine dipeptide of lipid II. 
Inhibitors of ribosomal protein synthesis 
Protein synthesis is a vital process performed within every bacterial species. The ribosome, together 
with transfer RNAs (tRNA) and messenger RNA (mRNA), is the functional unit of protein production 
through a process called translation. tRNAs are the molecules which ‘translate’ the mRNA into an 
amino acid sequence by matching codons and anti-codons from the mRNA and tRNA, respectively. 
The bacterial ribosome is constructed of a combination of multiple ribosomal RNAs (rRNA) and 
ribosomal proteins, which are divided into two subunits (50S and 30S). The large ribosome subunit 
(50S) is constructed of 23S rRNA, 5S rRNA and 32 ribosomal proteins.32 The 23S rRNA forms the 
highly structured pocket which houses the aminoacyl (A), peptidyl (P), and exit (E) sites.33 The P and 
A sites position the growing amino acid chain and the aminoacyl-tRNA to allow for peptidyl transfer 
through peptide bond formation. Prokaryotic ribosomes are smaller than those of eukaryotes, and they 
are sufficiently distinct in structure to allow for selective inhibition by some antibiotics. However, 
ribosomes within the mitochondria resemble those of bacteria, which may give rise to toxicity.18,32 
Chloramphenicol. The antibiotic chloramphenicol binds directly to RNA within the peptidyl 
transferase site of the ribosome, and inhibits peptide bond formation (Figure 1.8).18,34,35 The result is a 
loss of protein production, and consequently, the eventual death of the bacterial cell. Unfortunately, 
chloramphenicol toxicity involves bone marrow suppression in humans due to its interaction with 
mitochondrial ribosomes.18,36 Chloramphenicol is used clinically, although often as a second line of 
defense due to its adverse effects; nonetheless, it is on the WHO’s list of essential medicines.4 
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Figure 1.8: Structure of chloramphenicol, and its binding position within the peptidyl transferase site of 
the ribosome. Red: chloramphenicol, blue: ribosome, green: nascent protein, purple: mRNA. 
Disruptors of bacterial cell membranes 
The cell membrane is one of the essential structures of a bacterial cell (Figure 1.2). The membrane 
encloses the cellular contents and acts as a passive barrier to molecules in the environment. It is 
composed of a wide variety of lipid and protein molecules, which depend heavily upon the bacterial 
species. In the case of lipids, phospholipids are highly abundant. Two in particular are 
phosphatidylethanolamine (PE) and PG. All phospholipids contain a hydrophilic phosphate head group 
and hydrophobic fatty acyl tail; in an aqueous environment, this allows the spontaneous generation of 
a lipid bilayer due to the hydrophobic effect. A phospholipid bilayer corresponds to a significant 
fraction of the cell membrane and is characterized by a hydrophobic membrane core and hydrophilic 
surface. The organization of this structure is the basis for much of the restriction of passive diffusion 
of molecules. Polar molecules may not partition into the membrane, while hydrophobic molecules 
readily pass by partitioning into and then out of it again on the other side. Conversely, extremely 
hydrophobic molecules may become trapped within the hydrophobic membrane core.  
At generally half the mass of the membrane, proteins have important and highly regulated 
functions.33 Of note, are ion transporters, which actively transfer specific ions across the membrane, 
and  ion channels, which allow free movement of ions down a concentration gradient. These, together 
with the passive diffusion of ions through the cell membrane, establish a typical membrane potential of 
−40 to −80 mV, with respect to the outside of the cell.33 The potential is used as a source of energy for 
numerous metabolic functions, including bacterial cell division.37 
Nisin. The antibiotic nisin binds to the cell membrane through an interaction mediated by lipid II, 
and successively forms membrane-spanning pores. (Figure 1.9).38 Lipid II is the final monomeric, 
membrane-bound precursor in the synthesis of peptidoglycan, which is flipped across the membrane 
and exposed to the extracellular environment (Figure 1.3 IV). Notably, nisin’s interaction with lipid II 
is more complex than it acting as a ‘target molecule’. Research has shown that lipid II is a constituent 
of the nisin pore complex and is essential for stable pore formation.39 In contrast, model membrane 
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systems have shown the formation of nisin pores in the absence of lipid II; yet, these were formed at 
nisin concentrations 1,000-fold over the level required for formation of pores on model membranes 
supplemented with lipid II.39 In the case of bacteria, pore formation by nisin leads to the loss of ions, 
amino acids and ATP. This results in the eventual death of the cell through dissipation of the membrane 
potential, and loss of important intracellular molecules. Nisin is not used clinically, though it has 
potential; as of now it is solely used as a food preservative.40  
 
Figure 1.9: Structure of the lantibiotic nisin.The N-terminal portion is required for lipid II binding, while 
the C-terminal portion is necessary for membrane interaction. Amino acids: 2-aminobutyric acid (Abu), 
didehydroalanine (Dha), didehydroaminobutyric acid (Dhb), lanthionine (Lan; Ala-S-Ala), methyl-
lanthionine (MeLan; Abu-S-Ala). These unusual amino acids are introduced by post-translational 
modification of the precursor peptide. 
Daptomcyin.  In a comparable manner to nisin, dap has been shown to permeabilize bacterial cell 
membranes; although, whether this is the sole mechanism of action is still unclear (Figure 1.10). Pore 
formation, in this case, is mediated by an interaction with PG and calcium. The background and method 
of action of dap will be discussed in detail below, see section 1.2. 
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Table 1.1: Mechanism of action of select antibiotics 
Antibiotic Spectrum Mechanism of action 
Inhibitors of peptidoglycan synthesis 
Fosfomycin Gram+, Gram− Loss of activity through modification of an 
active site cysteine residue in enzyme murA 
Cycloserine Gram+, Gram− An analog of D-alanine which interferes with 
L-alanine racemase and D-alanine ligase by 
competitive inhibition 
Vancomycin(a) Gram+ Inactivation of cell wall transpeptidases 
through (a) blocking the substrate (b) 
irreversible inhibition of the active site Ampicillin(b) Gram+, Gram− 
Laspartomycin Gram+ Blocks undecaprenol, inhibiting production of 
lipid II 
Inhibitors of ribosomal protein synthesis 
Chloramphenicol Gram+, Gram− Blocks peptide bond formation in the 50S 
ribosomal subunit 
Disruptors of bacterial cell membranes  
Nisin Gram+ 
Loss of membrane potential due to pore 
formation 
Dapc Gram+ 
cSee section 1.2.4 for additional information 
1.1.2 Mechanisms of resistance 
Bacterial resistance is an increasingly serious problem across the globe. Many hospital-acquired 
infections are now attributable to multidrug-resistant bacteria. Infections of this kind can greatly worsen 
patient outcome.41 Antibacterial resistance can arise through three main pathways: natural resistance, 
genetic mutation, and acquired resistance. The first involves innate morphological and genetic 
differences between bacteria. The second may be spontaneous or mutagen-induced mutations, which 
diminish specific action modes. The third may pose the most critical difficulty for future antibiotic use; 
it involves transferable genetic elements such as plasmids, which allow for horizontal gene transfer 
between bacteria. This allows the transfer of existing genetic elements of antibacterial resistance 
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between bacteria, even across species barriers. As with action modes, mechanisms of resistance fall 
into a handful of broad classes. Below, these classes are briefly noted. For an overview of the 
mechanism of resistance of select antibiotics, refer to Table 1.2. 
Natural resistance. This arises by the absence of an antibacterial target in the organism. An example 
is the resistance of Gram+ bacteria to the polymyxin class of antibiotics. An essential part of the action 
mode of the polymyxins involves interaction with lipopolysaccharide (LPS).42 Gram+ bacteria, in 
contrast to Gram−, do not produce LPS. 
Target modification. Resistance to antibiotics which target essential cellular pathways are often by 
target modification.43 This occurs as the loss of target function may prove fatal to a cell. Target 
modifications can occur from point mutations in one gene, to changes in multiple gene pathways.30 In 
general, changes to the target reduce affinity for the antibiotic. 
Enzymatic degradation/modification. The antibiotic is modified or degraded to a point where it is no 
longer functional. This has large implications in clinical practice; it is a prevalent mechanism of 
antibiotic resistance and it dates back to the beginning of the antibiotic era with penicillin. It is also 
important for bacterial selection throughout scientific fields. Transformation of bacteria with antibiotic 
resistance plasmids which contain genes coding for antibiotic degradation or modification enzymes 
allows for the selection of resistant bacteria from those which are antibiotic-sensitive. 
Mutation to antibiotic transport. Many antibacterial agents require high intracellular concentrations 
to affect their respective targets. The inability of antibiotics to gain access to the bacterial cell interior, 
or the ability of bacteria to keep them out, can drastically reduce antibiotic effectiveness.  
Compensatory metabolic changes. There remains a broad set of mechanisms of resistance which 
occur in bacteria outside of those already listed. This set can be covered by the diverse metabolic 
changes which occur in bacteria. The changes often result in the up-regulation or down-regulation of 
lipids, enzymes, proteins, etc. This can then affect antibiotics in specific, or indirect, fashion. 
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Table 1.2: Mechanism of resistance of selected antibiotics 
Antibiotic Target Mechanism of resistance 
Inhibitors of cell wall synthesis 
Fosfomycin murA Mutation in transport pathways, ring 
opening by epoxide hydrolases44–46  
Cycloserine L-alanine racemase and D-
alanine ligase 
Mutation in the target enzymes, target 
overexpression 
Vancomycin  D-Ala-D-Ala of lipid II 
pentapeptide 
Mutation of amino acid sequence from D-
Ala-D-Ala to D-Ala-D-Lac30,43  
Ampicillin Transpeptidases Inactivation by β-lactamases44 
Inhibitors of ribosomal protein synthesis 
Chloramphenicol 50S ribosomal subunit       
(23S rRNA) 
Mutation of 23S rRNA, chloramphenicol 
acetyltransferase, reduced membrane 
permeability35,44,47 
Disruptors of bacterial cell membranes 
Nisin Lipid II Modification of lipid II sequence, enzymatic 
inactivation, cell wall and membrane 
composition48 
Dapa PG in bacterial membranes Adaptations in phospholipid membrane 
composition, bacterial esterases and 
deacylases49–52   
aSee section 1.2.6 for additional information 
1.2 Daptomycin 
Dap is a cyclic lipodepsipeptide antibiotic that belongs to the broader class of acidic lipopeptides.53 Its 
immediate family is designated A21978C.54–57 These natural antibiotics are produced by the 
microorganism Streptomyces roseosporus, which was discovered by the pharmaceutical company Eli 
Lilly.54 The A21978C family shares the same core macrolactone ring and exocyclic tripeptide (Figure 
1.10). The macrocycle contains 10 amino acids, 5 of which are D-amino acids or other non-
proteinogenic amino acids. These include ornithine (Orn6), D-Ala8, D-serine (D-Ser11), (2S,3R)-
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methylglutamate (MeGlu12), and kynurenine (Kyn13). The cycle is closed by a depsi bond between 
the hydroxy side chain of threonine (Thr4) and the α-carboxylic acid group of Kyn13. The exocyclic 
tripeptide consists of aspartic acid (Asp3); a third D-amino acid, D-asparagine (D-Asn2); and tryptophan 
(Trp1). The point of variance for the antibiotic family is the fatty acyl tail attached to the N-terminal α-
amino group of Trp1. Dap has an n-decanoyl acyl tail and is typically produced in low quantities by S. 
roseosporus; fortunately, Eli Lilly discovered that fermenting S. roseosporus with decanoic acid will 
produce dap in appreciable quantities.55 
 
Figure 1.10: The structures of dap and A21978C1-3 at physiological pH. The overall charge of dap is −3. 
1.2.1 Clinical use 
Clinical studies for intravenous dap were first carried out by Eli Lilly.54 In phase 1 trials that used a 
twice-daily dosage regimen, volunteers tolerated the antibiotic. In phase 2 clinical trials, the dose was 
increased to levels more effective against S. aureus bacteremia; volunteers began to develop adverse 
musculoskeletal effects and the trials were aborted. Later, Cubist Pharmaceuticals displayed interest 
and entered into licensing negotiations with Eli Lilly.  Negotiations were finalized in 1997, and Cubist 
began their independent clinical trials.54 It was discovered that a low once-daily dosage regimen 
avoided the adverse effects and retained antibacterial effectiveness.58  
Dap treatment of complicated bacteremia and right-sided endocarditis caused by S. aureus and 
MRSA met non-inferiority criteria against the standard therapy.59 However, dap performed poorly and 
did not meet the non-inferiority criteria against pneumonia.60 The low efficacy against pneumonia likely 
results from an interaction with pulmonary surfactant, which sequesters the drug.60 In 2003, dap was 
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approved by the Food and Drug Administration (FDA) under the name Cubicin for intravenous therapy, 
making it the only clinically used acidic lipopeptide. In 2014, Merck acquired Cubist Pharmaceuticals. 
1.2.2 The acidic lipopeptides 
The acidic lipopeptides are a new class of antibiotic, mostly produced by species of Streptomyces.53 
The class can be separated into two large families: the lipodepsipeptides, and the lipopeptides. The two 
families share many structural elements, such as the macrocyclic core and fatty acyl tail; however, the 
former, have a ring-closing depsi (ester) bond, while the latter, have a ring-closing amide bond. The 
lipodepsipeptides include dap, A54145 (A5), and calcium-dependent antibiotic (CDA).53 The 
lipopeptides include amphomycin, tsushimycin, and laspartomycin.53 Both families depend upon 
calcium for their antibacterial activity; however, as of now, the lipopeptides are known to act by a 
different mechanism of action than the lipodepsipeptides.28,29,61 A structural DXDG motif, which in dap 
comprises residues 7–10, is conserved between the families; it is presumed to be a calcium binding 
site.55,62 Disruption of either aspartic acid within the motif in dap completely abolishes activity.62 
Conservation of several D-amino acid sites also occurs.  
Other than dap, A5 is the most relevant lipodepsipeptides to this thesis. A5 encompasses a family of 
antibiotics, the natural host of which is the microorganism Streptomyces fradiae.53,63 As with A21978C, 
the A5 family shares the same core shape: a macrolactone ring to which is attached an exocyclic 
tripeptide bearing a fatty acyl tail. However, in addition to a variable tail, residues 12 and 13 can be 
substituted with MeGlu or glutamate (Glu); and valine (Val) or isoleucine (Ile), respectively.63 The 
macrocycle contains 10 amino acids, 5 of which are D-amino acids or other non-proteinogenic amino 
acids. These include sarcosine (Sar5), D-Lys8, 3-methoxyaspartic acid (MeOAsp9), D-Asn11, and 
sometimes MeGlu12. The cycle is closed by a depsi bond between the hydroxy side chain of threonine 
(Thr4) and the α-carboxylic acid group of Val or Ile. The exocyclic tripeptide consists of tryptophan 
(Trp1) and the non-proteinogenic amino acids D-glutamate (D-Glu2) and 3-hydroxyasparagine (HO-
Asn3). As with S. roseosporus, the quantity of a certain lipopeptide can be increased by supplementing 
S. fradiae with the amino acid precursors required for that variant.64 A5 is as potent as dap, however, it 
is clinically non-practical due to its increased toxic effects; substitutions to the amino acid sequence or 
acyl chain may allow for improved pharmacological properties.56,63 The variant used in our laboratory 
is “Factor D”, which has an anteisoundecanoyl acyl tail, Glu12, and Ile13 (Figure 1.11). 
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Figure 1.11: The structure of A5 Factor D at physiological pH. 
1.2.3 Biosynthesis 
Dap, like other the lipopeptides, is synthesized by its host organism non-ribosomally. S. roseosporus 
contains the DptE and DptF enzymes for initiation of synthesis, as well as three non-ribosomal peptide 
synthetases (NRPS) and other trans acting enzymes for elongation and cyclization. The three NRPSs, 
DptA, DptBC, and DptD are individually comprised of linear modules that in turn contain several 
distinct functional domains – the modules are responsible for incorporating five, six, and two amino 
acids, respectively.62 Each module contains a minimum of an adenylation (A-) domain, a condensation 
(C-) domain and a thiolation (T-) domain. The A-domains are responsible for the specific recognition 
and activation of an amino acid through adenylation with ATP to give AMP-amino acids. The AMP-
amino acids are transferred to the T-domains, with release of AMP, and formation of a thioester. The 
C-domains catalyze the ligation of amino acids on preceding and subsequent T-domains. Modules may 
also include epimerization (E-) domains; E-domains are responsible for switching the stereochemistry 
of the α-carbon of an amino acid. The modules which contain these E-domains give rise to the non-
proteinogenic D-amino acids in dap. After biosynthesis of the peptide it must be cyclized and released. 
This is accomplished by the unique thioesterase (TE-) domain located on the final module. 
To initiate synthesis, DptE and DptF activate the fatty acyl tail (FA, decanoic acid) for condensation 
to the nascent Trp1 amino acid. DptE, an acyl-CoA ligase homolog, ligates the FA to the acyl carrier 
protein DptF in an ATP-dependent manner. The first of the NRPSs, DptA, catalyzes the transfer of the 
FA from DptF to the N-terminal Trp1 with its C-domain. The FA substrate specificity of DptE is low; 
this is proposed to be responsible for the A21978C family variation.62 Amino acid chain elongation 
proceeds with transfer of the lipopeptide from DptA to DptBC, and finally to DptD. DptA and DptBC 
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contain the E-domains responsible for the epimerization of Asn, Ala, and Ser. DptD contains the 
module for the addition of MeGlu12 and the ultimate TE-domain.  The MeGlu12 amino acid is 
synthesized by the GlmT (glutamate 3-methyltransferase) enzyme DptI.62 The final TE-domain 
mediates formation of the depsi bond between the side chain of Thr4 and the α-carboxylic acid group 
of Kyn13. 
Biosynthesis of A5 follows a comparable route to that of dap. Whereas dap contains three NRPS 
genes, the A5 biosynthetic route contains four: LptA, LptB, LptC and LptD.64 The change of units 
results from DptBC, the largest NRPS from dap, being analogous to a fusion of LptB and LptC.64 The 
NRPS modules are responsible for incorporating five, two, four and two amino acids, respectively, and 
function with the same catalytic domains as dap, and an additional methylation domain. 
1.2.4 Mechanism of action 
Several action modes for dap have been proposed; among them, the dissipation of the membrane 
potential due to the interaction of dap with bacterial phospholipid membranes is best supported by 
experimental evidence. Potassium (K+) leakage from S. aureus cells interacting with dap and A21978C 
initially led researchers to explore the cell membrane as a site of action.65 Early results indicated that 
dap did increase the conductivity of planar bilayers in the presence of calcium and magnesium.66 
Antibacterial activity, unlike the conductivity changes, could not be replicated with magnesium.66 Dap 
is consequently said to be calcium-dependent; potent antibacterial activity requires around 1.25 mM 
Ca2+.56 Serendipitously, this concentration is similar to the normal level of free (as opposed to protein-
bound) calcium in human plasma.67 Dap activity also correlates to levels of the acidic lipid PG in the 
membrane (Figure 1.12).68 This correlation has been demonstrated on model membranes, as well as in 
B. subtilis.69,70 
 
Figure 1.12: Structures of phosphatidylglycerol (PG) and phosphatidylcholine (PC). PG is the major lipid 
necessary for dap activity. Phosphatidylcholine (PC) is the most abundant phospholipid in eukaryotic 
membranes, and mostly inert with respect to dap. The lipids are shown with myristoyl tails, but may vary.  
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The interactions of dap with model membranes have been principally characterized through 
fluorescence studies. In these, the intrinsic fluorophore Kyn13 has been advantageous. Early research 
showed that, upon the addition of calcium in the presence of PC membranes, Kyn13 fluorescence blue-
shifted and had an increased quantum yield.68,71 This indicated a decrease in the polarity of its 
environment, most likely due to membrane insertion. Addition of PG to these membranes yielded a 
significantly greater blue-shift and increase in Kyn13 quantum yield, suggesting deeper insertion.68 
Circular dichroism (CD) spectroscopy corroborated these results.68 Dap in the presence of calcium 
produced only a minor conformational change; dap with PC membranes in the presence of calcium 
produced another minor change. In contrast, dap with PC/PG membranes in the presence of calcium 
produced a significant conformational change. 
Membrane-permeabilizing proteins or peptides often form oligomeric structures on target 
membranes. Dap was shown to promote K+ leakage from bacterial cells, therefore it was suggested that 
it forms an oligomeric structure.72 Using fluorescence resonance energy transfer (FRET), the Palmer 
group showed oligomerization of dap on PC/PG liposome model membranes.73 The FRET donor was 
the intrinsic Kyn13 residue from native dap and the acceptor was an extrinsic nitrobenzoxadiazole 
(NBD) fluorophore attached to the Orn6 residue of dap (Figure 1.13). For FRET to occur between the 
two fluorophores, they must be in close proximity to each other within the membrane, which was 
interpreted as oligomerization. Oligomerization was detected at calcium concentrations relevant for 
antibacterial activity, suggesting that the oligomers could be the functional membrane defect. Later, 
quantitative analysis of FRET techniques was used to estimate the subunit stoichiometry of the 
oligomers; a number of 6 to 7 subunits was found.74 However, this study did not address how dap 
distributes between the two membrane leaflets, and due to limitations of the technique and assumptions 
made in the calculations, the estimated number of subunits may deviate from the true value. 
Oligomerization has also been detected with A5; the FRET donor was Trp1 from native A5 and the 
acceptor was an extrinsic acrylodan fluorophore attached to the Lys8 residue of A5 (Figure 1.13). 
 Furthermore, the NBD and acrylodan labels are both environmentally sensitive fluorophores capable 
of concentration-dependent self-quenching; this alone can be used to detect oligomerization. In 
oligomers of labeled dap or A5, the monomers should assemble in sufficient proximity to begin self-
quenching; the production of mixed oligomers, with the introduction of unlabeled peptides, should 
suppresses the self-quenching behavior by decreasing the mutual interactions of NBD or acrylodan 
labels.73 Without oligomerization, the extent of self-quenching should be unaffected by the presence of 
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unlabeled peptide. Comparison of the fluorescence of mixed and unmixed oligomers showed a 
suppression of self-quenching when unlabeled peptide was included, indicating oligomerization.73 
 
Figure 1.13: The structures of A5 and dap analogs used in the demonstration of oligomer formation on 
liposome model membranes. A5 analogs (top) include: A5-acrylodan (R1, R3) and A5-pyrene (R2, R4). Dap 
analogs (bottom) include: NBD-dap (R1, R3) and dap-perylene (R2, R4). 
The interaction of dap monomers on PC/PG liposome model membranes was further demonstrated 
by examining the excimer formation of perylene-labelled dap (Figure 1.13).75 Excimers, or excited 
dimers, are formed when an excited perylene monomer is in close proximity to one in the ground state; 
in fact, the interaction requires a closer approach of fluorophores than FRET.75 Pyrene is the most 
widely used label for studies such as these, however, perylene was used because pyrene has a monomer 
emission spectrum that overlaps with the absorption spectrum of the intrinsic Kyn13 residue; the 
overlap vastly reduces pyrene fluorescence due to energy transfer to Kyn13. The perylene label is 
attached through the N-terminus of the exocyclic Trp1 residue of dap, thereby replacing the native acyl 
tail. Consequently, the experiments probe the interaction of the acyl tail groups in the membrane. The 
experiments used conditions which mirrored those of the FRET experiments, thus oligomers were 
assumed to be forming. The resulting extent of excimer formation emphatically indicated oligomers 
were forming. Analysis showed dap had an extent of oligomerization of over 90% on equimolar PC:PG 
liposomes, and only slightly lower on bacterial membranes.75 Oligomerization was also found to be 
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driven by a stoichiometric interaction with PG. An exhaustive study of this phenomenon using A5 has 
recently been submitted.76 A5 avoids the problem of spectral overlap as it lacks a Kyn residue, thus 
pyrene can be attached to the N-terminal Trp1 residue (Figure 1.13). Furthermore, analysis of the 
spectrum is aided by the advantages of pyrene: greater excimer intensity and better spectral separation 
from the monomer signal. 
Despite the importance of demonstrating oligomerization, the presence of oligomers does not clearly 
indicate that they are important for antibacterial activity, or that a pore is being formed. Consequently, 
both FRET and excimer formation were used to search for the formation of hybrid oligomers of dap 
and CB-182,462, a semisynthetic derivative of A5, using NBD and perylene labels.77 The existence of 
the functionally impaired oligomers would indicate that oligomer formation is important for 
antibacterial activity.78 Hybrid oligomers were indeed formed, and when tested for antibacterial 
effectiveness, they showed a significantly reduced activity. This also shows that oligomerization is not 
sufficient for antibacterial activity; after formation, the oligomers must take an additional step in order 
to acquire a functional antibacterial effect.78 
Lastly, the presence of a functional pore was investigated using a liposome permeabilization assay 
which takes advantage of pyranine (Figure 1.14). Pyranine is a hydrophilic, fluorescence dye which 
can act as a pH-sensitive probe for the liposome interior.79 It is non-fluorescent at low pH, when the 
molecule is protonated on the phenolic hydroxyl group; deprotonation between pH 6 and 8.5 causes 
fluorescence emission at 510 nm. The assay consists of the generation of two opposite ion gradients, 
through the use of differing buffers – one being a proton gradient and the other a different ion, such as 
K+.80 The addition of a proton transporter, such as CCCP, will release a small quantity of protons, but 
dissipation of the proton gradient is prevented by the ensuing diffusion potential – this will not change 
the internal pH of the liposome as it is moderately buffered.80 The addition of dap will dissipate the K+ 
gradient only if it allows influx of K+ through a functional pore. Consequently, only in combination 
will the transporter and potential pore allow dissipation of the opposing ion gradients. This will 
overcome the internal liposome buffering capacity and the pH will increase; the pH increase stimulates 
pyranine fluorescence and indicates the lipopeptide is producing a functional pore. By changing the 
cation in the exterior buffer, as well as reversing the gradients to detect permeabilization of anions, dap 
was found to produce cation- and size-selective pores.80 
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Figure 1.14: Schematic of the pyranine-based liposome pearmeabilization assay. (A) Encapsulated 
pyranine with a H+ gradient inside and K+ gradient outside. (B) Application of the protonophore CCCP 
alone allows insignificant loss of protons. (C) If dap allows dissipation of the opposing K+ gradient, 
concurrent dissipation of the proton gradient occurs increasing pH and causing pyranine fluorescence.80  
An experiment-derived model of the structure of the dap pore was proposed by studying the 
interaction of dap with liposome model membranes containing cardiolipin (CL) in addition to PC and 
PG (Figure 1.20).52 CL has been implicated by genetic studies as a mechanism of resistance to dap by 
Enterococci.81 Within the model membrane system, incorporation of 10% CL was sufficient to inhibit 
pore formation, as measured by the pyranine-based permeabilization assay; this encompasses the upper 
range reported for bacterial membranes, suggesting that this mechanism may be relevant in vivo.52 
Estimation of the oligomer subunit number, by Kyn13 to NBD-dap FRET, on these membranes gives 
an oligomer of 4 subunits.52 The study mentioned above, estimated an oligomer of 6-7 subunits, but did 
not address how dap distributes between the two membrane leaflets, and may have provided an 
underestimate due to experimental limitations. The authors proposed that the decrease in oligomer size 
was due to CL suppressing translocation of dap from the outer leaflets of the membrane, to the inner 
leaflet. On high CL-containing membranes, dap would then remain as a tetramer on the outer leaflet; 
on susceptible membranes, translocation of tetramers would occur and the alignment of two tetramers 
in opposite leaflets would form a functional octameric pore (Figure 1.15).52  
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Figure 1.15: Model of dap on liposomes, with and without CL. (A) Formation of a dap tetramer. (B) 
Insertion into the membrane is limited by distension and creation of voids in the lipid acyl chains layer. 
This situation may be stabilized by addition of CL. (C) In the absence of CL, the lipid layer may cave in, 
forming the half-toroidal structure shown in (D). Finally, a tetramer which has flipped to the inner 
membrane through (D), may combine with a second tetramer in the outer leaflet, and produce an octameric 
pore.52 
To test the hypothesis, an experimental procedure to quench NBD-dap fluorescence was used.52 
Quenching occurs through reduction of NBD by dithionite. If NBD-dap is distributed as tetramers along 
both leaflets, any NBD-dap on the inner-leaflet would not be quenched, and half of the fluorescence 
would remain. However, as dap creates pores, and membranes are rather permeable to dithionite, a 
control was conducted using NBD-PE to show dithionite is excluded from the membrane interior 
(Figure 1.16A). Approximately half of the fluorescence was quenched; this indicates only the NBD-PE 
on the outer leaflet was reduced, even in the presence of dap’s pores. PC/PG membranes with NBD-
dap exhibited results similar to NBD-PE, showing only quenching of NBD-dap on the outer leaflet; 
therefore, half of the dap is translocating to the membrane interior. PC/PG membranes including 10–
20% CL had most of the NBD-dap fluorescence quench as dithionite was added (Figure 1.16B). This 
indicates dap is indeed confined to the outer leaflet by CL. In both, the remainder of fluorescence was 
slowly reduced, likely due to subsequent translocation from the inner leaflet to the outer leaflet. 
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Figure 1.16: NBD-dap fluorescence quenching assay, using dithionite. (A) A control showing dithionite is 
excluded from the liposome interior in the presence of dap pores. (B) In PC/PG membranes including 10-
20% CL most of the NBD-dap fluorescence has been reduced by dithionite instantly. This indicates it is 
confined to the outer leaflets.52 
More recently, the interaction of dap and A5 with calcium has been established in more detail. The 
requirement of calcium for the activity of dap has long been recognized, but the molecular details and 
stoichiometric ratio of calcium to dap were not well characterized. To date, as described above, CD 
experiments described two possible calcium-dependent conformational changes in dap: one with 
calcium and dap in solution, and the other in the presence of PG-containing membranes. Also, NMR 
studies of dap in solution have indicated that calcium binds to dap in solution with a 1:1 
stoichiometry.68,82,83 Isothermal titration calorimetry (ITC) studies have now shown that dap binds two 
calcium ions per lipopeptide molecule and that the two ions are bound successively and with different 
affinity.84 Furthermore, fluorescence studies have shown that the two successive calcium-dependent 
transitions mediate the membrane binding and oligomerization of dap and A5.84 
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Figure 1.17: Fluorescence spectra of tryptophan from A5 (left) and acrylodan from A5-acrylodan (right) 
in the presence of 70:30 PC:PG liposomes and increasing Ca2+ concentration (mM) at 37 °C. Trp and 
acrylodan excitation wavelengths are 280 nm and 360 nm, respectively. 
The fluorescence studies used separately incubated dap and dap-acrylodan, and A5 and A5-
acrylodan. Above, the fluorescence spectra of A5 and A5-acrylodan are shown and will be used as an 
example; the fluorescence was observed as calcium was added incrementally from 0 to 50 mM. The 
intrinsic Trp1 fluorophore of A5 shows no response up to 0.1 mM but then rapidly blue-shifts (left: 
Figure 1.17). In contrast, the fluorescence of A5-acrylodan rapidly peaks at 0.1 mM Ca2+ but then 
decreases at higher concentrations (right: Figure 1.17). 
 
Figure 1.18: Mean tryptophan wavelength emission of A5 compared to maximum fluorescence intensity of 
A5-acrylodan emission (I472), each as a function of Ca2+ concentration. Liposome composition is 50:50 
PC:PG. Legend: A5A refers to A5-acrylodan. 
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Directly comparing the mean tryptophan wavelength emission of A5 and the maximum fluorescence 
intensity of A5-acrylodan emission as a function of calcium concentration, clarifies the different 
responses (Figure 1.18). As calcium is increased, the Lys8 residue bearing the acrylodan label binds to 
the membrane and its fluorescence both increases and blue-shifts; at 0.1 mM Ca2+ the residue is fully 
inserted. Further increasing calcium causes Trp1 to bind the membrane and blue-shift; concomitantly, 
the acrylodan labels begin to self-quench. As mentioned above, the self-quenching of acrylodan is 
interpreted as oligomerization.73 
A second study using A5-pyrene found some complementary findings.76 Two successive calcium-
dependent transitions were observed at similar calcium concentrations seen above. The first transition 
displayed interaction of the fluorophore-labeled acyl tail of monomers through excimer formation, 
indicating oligomerization; the second transition displayed increased excimer intensity, indicating a 
tighter interaction of the acyl residues or a larger number of subunits.76,84 Together, the studies suggest 
a mechanism of dap membrane binding and oligomerization wherein the first calcium ion causes 
lipopeptide monomers to bind to the membrane and to form a loosely associated structure, in which the 
acyl tail interact but not portions of the lipopeptide head group; increased calcium concentration induces 
the binding of a second calcium ion and the initial structure transitions to a tightly associated and 
functional oligomer.76,84 From here, the oligomers could translocate and form the pore required for 
leakage of cellular ions. 
The latest preliminary work using A5-acrylodan has shown that the self-quenching action may report 
more directly on the translocation/pore formation of dap or A5, rather than the oligomerization. This 
would change the interaction of the acrylodan labels from between subunits within an oligomer on a 
specific membrane leaflet, to an interaction of acrylodan labels between separate oligomers on opposing 
membrane leaflets. This proposal arises from the suppression of A5-acrylodan self-quenching on CL-
containing membranes. CL at concentrations of 10% or higher has been shown to confine dap to the 
outer membrane leaflet and abolish pore-dependent membrane permeabilization.52 The two calcium-
dependent transition described above may then indicate initial oligomerization and subsequent 
oligomer translocation and cross-leaflet alignment. 
1.2.5 Daptomycin analogs 
Dap analogs are a valuable tool to establish the structure-activity relationship (SAR) of dap. Altering 
the structure of the antibiotic allows for characterization of the specific role of different amino acids in 
the overall activity. Substitutions to specific amino acids may also improve pharmacological properties 
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such as antibacterial activity, spectrum, toxicity. Generation of analogs resistant to sequestration in 
surfactant is also possible. Four approaches to producing different analogs are genetically engineered 
biosynthesis, chemoenzymatic synthesis, semi-synthesis, and total synthesis.  
Genetically engineered biosynthesis, or combinatorial biosynthesis, manipulates the NRPS modules 
to substitute single or multiple amino acid sites. In one study, S. roseosporus was altered to have 
deletions in NRPS modules. Plasmids were transferred through conjugation with Escherichia coli to 
functionally complement the missing modules.62 This was used to generate analogs with Ile13 or Trp13 
instead of Kyn13. Combinatorial methods have also been used to produce hybrids of A5 and dap. The 
antibacterial activity of A5 (Factor E) is inhibited 32-fold in 1% surfactant, whereas that of dap is 
inhibited 128-fold; dap analogs including portions of the amino acid sequence of A5 may then prove 
an easy method to increase activity against Streptococcus pneumoniae in vivo.85 Many analogs were 
generated; several were less inhibited by surfactant but also comparatively less active against S. aureus 
than dap. 
Semi-synthesis is the process of altering the chemical structure of molecules through organic 
chemistry. An early experiment used semi-synthesis to investigate the significance of Asn2 
stereochemistry.86 The fatty acyl tail attached to Trp1 was first enzymatically removed to allow access 
to the N-terminus of an Orn6-protected dap. Edman degradation was used to remove Trp1 and Asn2, 
and the resulting undecapeptide was reacted with N-decanoylated L-Trp-D-Asn and L-Trp-L-Asn 
dipeptides. The L-Asn isomer showed a 10-fold increase in MIC, indicating the stereochemistry at this 
position is important. Using similar chemistry, the Trp1 residue was also replaced or modified in an 
attempt to increase the activity of dap in lung surfactant. Attachment of electron-withdrawing groups 
to the aromatic portions of Trp1 tended to improve or preserve activity, but also to increase the negative 
effect of surfactant; electron-donating groups generally had the opposite effect, and groups with 
hydrogen-bond donor sites were mostly inactive.87 Synthetic methods to attach fluorophores to the Orn6 
and fatty acyl tail have also been advantageous in studies of the mechanism of action of dap.52,73,75,78  
Chemoenzymatic synthesis uses bacterial enzymes such as peptide cyclases (NRPS TE domains) and 
organic, or biological, synthesis to produce analogs. Advances in the sequence information for dap and 
A5 allowed the cloning and expression of their native TE enzymes.62 Multiple amino acids were 
substituted, including MeGlu12, Kyn13, Asp3, and the acidic amino acids in the in the DXDG motif 
that comprises residues 7–10 in dap. Exchange of Asp7 or Asp9 with Asn eliminated all antibacterial 
activity, however, the substitution of Asp3 with Asn only slightly decreased activity.62 This 
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corroborates the theory that the acidic members of the DXDG motif are involved in calcium binding. 
Nguyen et al.88 conducted many substitutions: (1) MeGlu12 with Glu increased MIC 16-fold. (2) Kyn13 
with Trp, Ile, or Val increased MIC 2-, 4-, and 8-fold. (3) D-Ser11 with D-Ala or D-Asn increased MIC 
2-fold. (4) D-Ala8 with D-Ser or D-Asn increased MIC 2- and 16-fold. That some substitutions did not 
highly affect the MIC against the bacteria is advantageous as amino acids in these positions may be 
able to be changed to give rise to beneficial pharmacodynamics or pharmacokinetic effects.  
Total synthesis is the newest method to generate dap analogs and has begun to develop into a 
powerful tool. The total synthesis of dap is difficult due to the characteristics of the lipodepsipeptide, 
which includes non-proteinogenic amino acids, cyclic structure, and the fatty acyl tail; racemization of 
amino acids and hydrolysis of the depsi bond are also concerns. However, these obstacles have mostly 
been overcome. This allows total synthesis to have wide selection of targets for substitution, which will 
allow for a more comprehensive look at the SAR of dap. Three full dap syntheses have been published. 
Two include a patent by Cubist and an article by Lam et al.77 The latter used a combination of solution 
and solid-phase techniques and has begun producing new analogs. The last synthesis is the first full 
solid-phase peptide synthesis (SPPS) of dap, developed by the Taylor group.89 SPPS techniques are 
conducive to the generation of combinatorial dap analog libraries, which would improve the speed of 
discovery of significant analogs. New analogs have been produced, most notably, dap-E12-W13, which 
does not contain Kyn13 or the synthetically challenging MeGlu, but retains an MIC similar to dap.89 
1.2.6 Mechanisms of resistance 
Dap resistance was observed early in its clinical application but remains relatively rare. Reports from 
clinical trials conducted by Eli Lilly and Cubist detailed three resistant strains.9,90,91 The reports from 
Cubist involved immunocompromised patients with bacteremia. The first case involved a vancomycin-
resistant Enterococcus faecium with an original dap MIC of 2 µg mL-1, which increased to 6 µg mL-1 
when isolated 17 days later.91 The second case involved a methicillin-resistant S. aureus with an MIC 
of  ≤1 µg mL-1, which increased to 2 µg mL-1 when isolated 27 days later.9 While resistant clinical 
isolates are readily available, selecting for resistant bacteria in the laboratory is tedious. Eleven strains 
with dap resistance were recovered after using methyl-nitrosoguanidine mutagenesis and serial passage 
with increasing concentrations of dap for 21 days.92 In either case, clinical and laboratory-manufactured 
non-susceptible bacteria are useful subjects for study into antibiotic mechanisms of resistance.  
One group, using S. aureus with induced resistance, was able to discover several genetic changes 
that correlate to increased resistance to dap.51 The non-susceptible strains used were recovered via a 
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method similar to that detailed above. To determine the genetic basis of the resistance, the authors used 
full genomic comparisons of the resistant bacteria and their susceptible parent. Two different proteins, 
with amino acid substitutions due to single point mutations, were correlated to resistance: YycG and 
MprF. Furthermore, these proteins were also shown to be relevant to non-susceptible bacteria from 
clinical isolates.51 
YycG is a member of the two-component system YycFG (now termed WalRK) from the yyc operon 
first discovered in B. subtilis.93 The system is conserved throughout many low-GC Gram+ bacteria, 
including S. aureus. YycG is a membrane-spanning sensor/histidine kinase, and YycF is a response 
regulator.55,93 Autophosphorylation of YycG and phosphotransfer to YycF, indicate these proteins are 
part of a bacterial signal transduction cascade.93 In B. subtilis, YycG localizes to the cell division septum 
and is involved in cell division and cell wall restructuring.94 DNA analysis of the components in S. 
aureus reveal similarities to those in B. subtilis, showing regulation of target genes that control cell 
wall metabolism, membrane-bound transport systems, and virulence.93 Using a recombinant yyc operon 
with an inducible promoter, the S. aureus operon was also found to be essential for growth at 37 °C. 
Depletion of the YycFG system through inhibition of transcription causes cell death without lysis.  
The fashion in which YycFG in susceptible and non-susceptible bacteria potentially interact with dap 
is not known. It could be possible that in susceptible bacteria dap binds to YycG and inhibits signal 
transduction to the response regulator. This would cause cell death in the same fashion as depletion of 
the protein. Dap-resistant strains would have mutant YycG proteins with lessened binding affinity for 
the antibiotic. There is no direct evidence of dap binding to YycG; however, Gram− bacteria lack the 
two-component system and dap is not active against them. The outer membrane (OM) formed by 
Gram− bacteria is often demonstrated as the reason for the increased resistance, but not in the case of 
dap.95 Nisin – a cell membrane-active antibiotic – has an MIC of 2 µg/mL on S. aureus. On E. coli the 
MIC increases to >64 µg/mL; removal of the E. coli OM decreases the MIC to 8 µg/mL. Dap on S. 
aureus gives an MIC of 2 µg/mL. On E. coli the MIC increases to >256 µg/mL; in the absence of the 
OM, the MIC does not change. Nevertheless, this does not preclude other factors which may cause dap 
to have ineffective activity on Gram− bacteria, such as efflux transporters and a much lower PG 
content.95 
MprF, or multiple peptide resistance factor, has been characterized as an LPG synthetase. LPG is 
synthesized through the transfer of L-lysine from lysyl-tRNA to PG; this reverses the −1 charge of PG 
to +1.96 MprF gain-of-function mutants have been associated with increased resistance to many cationic 
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antimicrobial peptides (CAMPs), such as host defense antimicrobial peptides (HDPs).97 As with dap, 
many HDPs initially interact with the bacterial cell membrane, but their subsequent mechanisms of 
action can be different.98 MprF was first characterized in S. aureus through gene deletion, 
complementation and recombinant trans-expression in E. coli.99 Two separate functions have been 
assigned to the C- and N-terminus.96 The hydrophilic C-terminal domain contains the synthetic 
machinery, while the hydrophobic N-terminal domain contains a lipid flippase. Incorporation of the 
MprF N-terminus alone did not confer CAMP resistance; in addition, incorporation of the MprF C-
terminal alone did not lead to effective CAMP resistance.96 Only when overexpressed together as one 
protein, or two, did the MprF C- and N-terminals successfully mediate full-level CAMP resistance. 
This indicates that CAMP resistance is dependent upon both increased LPG synthesis and its 
concomitant exposure to the outer surface of the membrane.96 
 
Figure 1.19: Model for the mode of MprF-mediated bacterial CAMP resistance.96 
The proposed mechanism through which MprF gain-of-function mutants decrease susceptibility to 
CAMPs is decreased membrane association. The reduced interaction is presumed to occur through 
electrostatic repulsion between the increased relative positive charge of the bacterial membrane and the 
cationic antibiotics (Figure 1.19).96 In relation to dap resistance, the mechanism has yet to be 
characterized, but can potentially act in a similar manner; dap, in conjunction with calcium, would 
supposedly act in a CAMP-like manner and the upregulation of LPG renders the mutant bacteria less 
susceptible by repelling the lipopeptide. 
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Figure 1.20: Structures of cardiolipin (CL) and lysyl-phosphatidylglycerol (LPG). CL and LPG are 
correlated to dap resistance. 
Two other cell membrane composition changes have been implicated in dap resistance.  The first is 
the down-regulation of PG. In both S. aureus and B. subtilis, this occurs through a mutation in the pgsA 
gene, whose product is an enzyme within the PG synthesis pathway.70,100 As dap is reliant on PG for its 
mechanism of action, a reduction in the cell membrane concentrations reduces dap’s effectiveness. The 
second is an up-regulation of cardiolipin. It was discovered by Palmer et al.,81 who used serial passage 
over two weeks to induce resistance to dap in Enterococcus faecalis. Whole-genome sequencing was 
then used to compare the resistant bacteria and their susceptible parent. Mutations were studied for their 
putative effects, and also compared to E. faecalis clinical isolates. One mutation, EF0631, was found 
to reside within a cardiolipin synthase; when compared a similar mutation was also found within a dap-
resistant E. faecalis clinical isolate. Cardiolipin is proposed to confer resistance through the prevention 
of dap oligomer translocation from the outer membrane leaflet to the inner membrane leaflet.52 This 
results in a loss of bacterial permeabilization, and consequently no change in membrane potential. 
Degradation processes have also shown to increase resistance to dap. A group of 60 environmental 
actinomycete strains were showing high dap resistance (≥ 256 µg/mL). D’Costa et al.49 demonstrated 
the bacteria were degrading dap through multiple hydrolytic mechanisms. HPLC and mass 
spectrometry results on the soil isolate library concluded there was ester hydrolysis, deacylation and 
secondary degradation by the bacteria. Ester hydrolysis refers to the cleavage of the depsi bond between 
Kyn13 and the side-chain of Thr4 and was the predominant method of deactivation. Deacylation was 
the second most prevalent and refers to the removal of the n-decanoyl acyl tail. Both of these 
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mechanisms have been shown previously to eliminate all antibacterial activity.15 Secondary degradation 
was most often due to cleavage between Trp1 and D-Asn2, and Kyn13 and MeGlu12. 
1.3 Discovery of bacterial L-forms 
In 1935, Emmy Klieneberger discovered a new form of bacteria; they were entitled “L” forms, after 
the Lister Institute in which she worked.101,102 L-forms are capable of growth and division without a 
cell wall.103 Many L-forms have the ability to revert to the parental cell-walled state (N-form). L-forms 
able to revert are called unstable, while those who cannot are stable. Unstable L-forms are considered 
genetically identical to the parent N-form; stable L-forms are genetic mutants, which show some 
differing characteristics compared to their parent N-form.104 
The originally discovered L-forms were naturally derived. Researchers soon discovered that L-forms 
can be induced through chemical means. In all cases, the inducer affects the stability of the cell wall 
which allows for the transition to L-form, where propagation in this form can begin. In the case of both 
induced and naturally-derived L-forms, growth must occur on a suitable medium; the cell wall, in 
addition to providing shape and rigidity, protects bacteria from osmotic lysis in the presence of 
hypotonic solutions. In general, this means the wall-less bacteria need an osmotically enriched medium. 
Sodium chloride (1–5%) and sucrose (5–20%) are commonly used as osmoprotectants.105 Divalent 
cations such as magnesium can also be used to stabilize the cytoplasmic membrane.105,106 
1.3.1 Creation of B. subtilis PDC 134, an efficient producer of L-forms 
Conventional methods for the production and propagation of stable L-forms are tedious. This makes 
obvious the importance of a bacterial strain which can stably convert from the N-form to the L-form in 
a quick and efficient manner. Domínguez-Cuevas et al.107, with initial research by Leaver et al.108, 
developed and isolated such a strain. The bacteria they produced was a transformed and mutated B. 
subtilis 168 strain called PDC 134. B. subtilis PDC 134 contains a xylose promoter (Pxyl) fused to the 
beginning of its chromosomal murE operon; the murE operon is important for peptidoglycan synthesis 
as it contains the enzymes required for multiple steps in the synthetic pathway.109 In the presence of the 
inducer, xylose, the xylose repressor (xylR) is removed from Pxyl and the growth rate and shape of the 
cells is normal (N-form). In the absence of the inducer, xylR remains and peptidoglycan synthesis is 
repressed; this causes the cells to transition to L-form. To reduce background expression from the 
promoter and reduce spontaneous reversion through mutations in the xylR gene, an additional copy was 
added.107,110 
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The other mutations in PDC 134 were characterized by sequencing the genome and comparing to the 
‘wild-type’ B. subtilis 168 genome and relevant laboratory strains. Of the polymorphisms, two were 
found to be significant towards the formation of L-forms: sepFT11M and walRR204C.107 The sepF gene 
codes for a cell division protein that binds to the FtsZ protein, and is essential for proper cell division; 
the mutants, such as sepFT11M, are viable but division septa have abnormal morphology.111,112 The walR 
gene codes for the WalR protein, which is the response regulator in the WalRK (formerly YycFG) two-
component system that regulates cell wall metabolism by controlling expression of autolysins.94  In 
dividing cells, WalRK upregulates autolysin to break down peptidoglycan and allow for growth; in 
non-dividing cells autolysin activity is down regulated.94 The walRR204C mutation of the PDC 134 strain 
leads to partially constitutive WalR activity, which allows for sustained autolysin activity. These 
mutations aid in the efficient and high frequency of L-form transition in the  PDC 134 strain; this likely 
occurs due to their aberrant peptidoglycan layer facilitating breach points which allow for the 
emergence of the protoplast.107 
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Chapter 2 
Characterizing an acyl-linked dimer of daptomycin 
2.1 Introduction 
Membrane-permeabilizing proteins or peptides often form oligomeric structures on target membranes. 
Since dap causes K+ leakage from cells, it was suggested that it forms an oligomeric structure.72 Later, 
oligomerization was unequivocally detected and found at calcium concentrations relevant for 
antibacterial activity.73 It is now known that oligomer formation is a necessary but not sufficient 
condition for pore formation, the end result required for antibacterial activity.52,78 Due to the necessity 
of oligomerization for antibacterial action, studying the effects of alterations to its progression is 
important. 
One method of altering the process of oligomerization is to change its entropy cost. This might be 
accomplished by producing partially ‘pre-oligomerized’ dap molecules. By reducing the entropy cost 
of oligomer formation, the activity of the analog might increase. No high-resolution structure of dap 
oligomers or pores have been generated; thus, the question of how to synthesize a pre-oligomerized dap 
analog remains uncertain. Fortunately, a working model derived through fluorescence experiments has 
been proposed by the Palmer group.52 Dap was suggested to assemble into tetramers; on susceptible 
membranes, translocation of tetramers would occur and the alignment of two tetramers in opposite 
leaflets would form a functional octameric pore.52 Within oligomers, the acyl tails of monomers have 
been shown to directly interact. This was characterized by the production of excimers in a perylene-
labeled dap analog.75 Consequently, an acyl-linked dap dimer has the potential to remain active, as its 
point of dimerization ought not introduce extensive steric constraints (Figure 2.1). 
Characterization of the acyl-linked dimer of dap is possible through assays which indicate membrane 
binding, pore formation, and antibacterial activity. Membrane binding is detected in the presence of 
liposomes or bacteria by calcium-dependent increases to the quantum yield of dap’s intrinsic Kyn13 
fluorophore.  Pore formation is detected with a liposome permeabilization assay which displays pore-
dependent increases in the fluorescence of liposomes loaded with a pH-sensitive dye. Antibacterial 
activity is measured through minimum inhibitory concentration (MIC) assays on susceptible bacteria. 
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Figure 2.1: Structure of the acyl-linked dap dimer. 
2.2 Materials and Methods 
Lipids used in the preparation of liposomes were purchased from Avanti Polar Lipids, Inc. (Alabaster, 
AL, USA). Bacillus subtilis PDC 134 was generously provided by the Centre for Bacterial Cell Biology, 
Institute for Cell and Molecular Biosciences (Newcastle upon Tyne, UK). Daptomycin was provided 
by Jared Silverman (Cubist Pharmaceuticals, Inc; Lexington, MA, USA). Fluorescence studies are done 
on a QuantaMaster 4 spectrofluorimeter (Photon Technology International, London, ON). Calcium is 
used as CaCl2. The acyl-linked daptomycin dimer was produced semi-synthetically by Dr. Scott Taylor 
(University of Waterloo; Waterloo, ON.); high purity was assessed by HPLC and mass spectroscopy. 
2.2.1 Preparation of liposomes 
The lipids (PG, PC, LPG, PS) are weighed to the corresponding molar ratios and transferred to a clean 
round bottom flask. The lipids are of the saturated dimyristoyl variety, with the exception of LPG, 
which is an unsaturated dioleoyl lipid.  The lipids are dissolved in chloroform and methanol (3:1) and 
then dried under a stream of purified nitrogen gas to form a thin lipid film. Further drying is performed 
for 3 or more hours under vacuum. The lipid films are used immediately, or stored until hydration at 
−20 °C. Before use, the lipids are left to warm to ambient temperature and then hydrated by addition 
of 3 mL of buffered solution and mixing until homogeneous, for a final concentration of 5 mM. 
Liposomes (large unilamellar vesicles, LUVs) of a defined and homogeneous size are produced by 
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repeatedly extruding the mixture through a 100 nm polycarbonate membrane with pressurized nitrogen. 
The average diameter of the liposomes approximates the pore diameter of the polycarbonate 
membrane.113 The liposomes are stored in glass vials at 4 °C until use. Liposomes containing LPG need 
to be used immediately due to instability. 
2.2.2 Preparation of B. subtilis PDC 134 L-forms for fluorescence studies 
B. subtilis strains are grown in their respective medium from frozen stocks (−80 °C); 5-100 µL of 
culture is used to inoculate 5 mL of medium in a 50 mL flask (1:10 allows for proper air flow). B. 
subtilis ATCC 1046 is grown in Luria-Bertani (LB) broth. B. subtilis PDC 134 N-form is grown in LB 
supplemented with 0.5% xylose. B. subtilis PDC 134 L-form is grown in osmoprotectant LB 
supplemented with Mg2+ (20 mM), maleic acid (20 mM), and sucrose (500 mM; MSM LB). ATCC 
1046 and PDC 134 N-forms are grown overnight, while PDC 134 L-forms require 3 to 4 days. L-forms 
are incubated at 30 °C, while the others can be grown at either 30 °C or 37 °C. After growth, the cells 
are washed twice with HEPES-buffered saline (HBS; supplemented with 500 mM sucrose for L-forms) 
with use of a centrifuge (1500×g for 20 min, for L-forms). The final pellet is re-suspended in the 
standard, or osmoprotectant, HBS buffer and the optical density at 600 nm (OD600) is determined. The 
cells can also be microscopically visualized to ensure proper morphology. For the isolation of PDC 134 
N-forms and L-forms see sections 6.2.1 and 6.2.2. 
2.2.3 Fluorescence studies 
Liposomes of a given molar ratio are prepared, as described previously. The hydration buffer is HEPES-
buffered saline (HEPES, 20 mM; NaCl, 150 mM; pH 7.4). For optimum signal, the samples contain a 
total lipid concentration of 250 µM, and a final lipopeptide analog concentration of 3 µM. Calcium is 
added step-wise titration as indicated in the results; upon addition of calcium the samples are mixed 
and then incubated for three minutes. If bacterial cells are used, a variable volume of cell suspension is 
added to reach an OD600 of 0.4. Cell samples are prepared as described previously. If surfactant is being 
used in place of liposomes, it is added to a concentration of 1 percent. Excitation wavelength is chosen 
depending on the appropriate lipopeptide fluorophore (Table 2.1). Controls include measurements of 
the liposomes alone and the lipopeptide alone. 
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Table 2.1: Fluorophore, excitation wavelength, and emission range of relevant lipopeptide analogs. 
Lipopeptide Fluorophore Excitation (nm) Emission (nm) 
Dap Kyn13 365 400–600 
Dap dimer Kyn13 365 400–600 
2.2.4 Determining the antibacterial activity of antibiotics 
The antibiotics were tested for their specific antibacterial activity by broth dilution in a 96-well plate. 
The antibiotics were added at varying concentrations until the MIC was found; each concentration is 
tested 9 times. Osmotically stable bacterial strains (ATCC 1046, PDC 134 N-forms) used LB broth, 
while osmotically sensitive bacterial strains (PDC 134 L-forms) used MSM LB broth (Mg2+, 20 mM; 
maleic acid, 20 mM; sucrose, 500 mM). The media was additionally supplemented with 5 mM calcium 
for calcium-dependent antibiotics. Each well was inoculated with the appropriate bacterial strain 
(ATCC 1046, PDC 134 N-forms, PDC 134 L-forms) and incubated at 30 °C overnight (N-forms) or for 
3 days (L-forms). Bacterial growth in each well was evaluated visually by turbidity. 
2.3 Results 
Initial antibacterial activity tests indicated that the dap dimer did not have increased activity compared 
to the native antibiotic; rather to the opposite, the MIC of the dimer increased from 0.75 µg/mL for the 
native monomer to over 100 µg/mL (Table 2.2). It was possible that dimerization inhibited a necessary 
step for antibacterial activity, such as membrane binding, oligomerization, or pore formation; therefore, 
determination of membrane binding was examined using the standard membrane binding assay on a 
liposome model membrane. The chosen membrane composition was 70:30 PC:PG, representing a 
simple dap-sensitive membrane; PG is required for the action mode of dap, while PC is mostly inert 
lipid with respect to dap at low calcium concentrations. 
  37 
  
Figure 2.2: Kynurenine fluorescence spectra of dap and the dap dimer in the presence of 70:30 PC:PG 
liposomes and increasing Ca2+ concentration (mM) at 37 °C. 
The fluorescence spectra show that as calcium is added incrementally, the quantum yield of Kyn 
increases, indicating membrane binding (Figure 2.2). The loss of antibacterial activity by the dap dimer 
is thus not due to inhibited interaction with the membrane. In fact, the fluorescence intensity response 
of the dap dimer is comparatively higher at low calcium concentrations than dap. Visualization of the 
difference in response can be improved by plotting maximum Kyn fluorescence as a function of calcium 
(Figure 2.3). 
 
Figure 2.3: Kynurenine fluorescence of dap and dap dimer on liposomes of varying composition at 37 °C.  
The figure follows maximum normalized analog fluorescence (I442) as a function of Ca2+ concentration.  
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The data displays a clear shift in the dimer’s fluorescence intensity response at low calcium 
concentrations. Only by 1 mM Ca2+ is the difference in relative fluorescence minimal, and at this 
concentration both dap and the dimer display nearly saturated fluorescence. The fluorescence shift may 
be a product of the assumed reduction in oligomerization entropy cost; in the assay the fluorescence of 
membrane binding is not differentiated from that of oligomerization. However, despite the antibiotic 
responding at lower calcium concentrations, it did not correspond to increased antibacterial activity. 
Subsequently, the dap dimer was examined for the production of a functional pore. This was tested 
using a fluorescence-based liposome permeabilization assay. Preliminary data shows that the dimer 
forms functional pores (data not shown). Since the dimer appeared to be active on model membranes 
but not bacterial cells, it was considered that the peptidoglycan layer might be responsible for the loss 
of activity against cells. This was plausible as native dap has been seen to bind to bacterial cell walls 
which lack any cell membrane in the presence of calcium.114 In order to test this hypothesis, the activity 
of the dimer was examined on B. subtilis  PDC 134 L-forms; the L-form bacteria are able to propagate 
without a cell wall, making them perfect test organisms (Table 2.2). 
Table 2.2: MIC (µg/mL) of dap and dap dimer on B. subtilis strains. 
Antibiotic B. subtilis strain 
 ATCC 1046 PDC 134 (N-form) PDC 134 (L-form) 
Dapa 0.75  0.5–0.75 0.075 
Dap dimera >100 30 0.2–0.25  
a5 mM Ca2+    
Dap and the dap dimer presented with and MIC of 0.075 µg/mL and 0.20 µg/mL, respectively, on 
the cell wall deficient L-forms. Thus, removal of the cell wall restores most of the activity to the dimer, 
suggesting the peptidoglycan layer may sequester the dimer or otherwise restrict its access to the cell 
membrane. Removal of the cell wall is also greatly beneficial to the activity of native dap. Dap and the 
dap dimer presented with and MIC of 0.75 µg/mL and 30 µg/mL, respectively, on the cell walled N-
form of B. subtilis PDC 134. The difference in activity between B. subtilis ATCC 1046 and PDC 134 
N-forms may arise from the mutations in PDC 134 that affect cell wall integrity; for example, increased 
autolysin activity and aberrant division septa.107 These mutations are essential to the strains efficient 
transition to the L-form; the protoplast must escape the peptidoglycan layer to propagate in its cell wall 
deficient form. The decrease in cell wall integrity allows for breach points within the peptidoglycan. 
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Table 2.3: MIC (µg/mL) assay results using dap and the dap dimer at 5 and 100 mM Ca2+ on B. subtilis 
ATCC 1046. 
 Ca2+ Concentration 
Lipopeptide 5 mM 100 mM 
Dap 0.75 0.50 
Dap dimer >100 5.0 
 
Interestingly, high calcium concentrations are able to restore reasonably high antibacterial activity to 
the dap dimer (Table 2.3). The physical constraints of dimerization likely do not affect the calcium 
affinity of the lipopeptide, as the charged head group is unaffected. Other factors must then account for 
the activity change, one might be a reduction in electrostatic repulsion. In Gram+ bacteria, the teichoic 
acids throughout the cell membrane and cell wall are the primary carriers of negative charge. The lipo- 
and wall teichoic acids and are known to bind calcium.115 NMR studies of dap in solution have indicated 
that Ca2+ binds to dap in solution with a 1:1 stoichiometry; this would leave dap in solution as a singly-
charged anion.82,83 Theoretically, the dimer would bind calcium in solution in a 2:1 stoichiometry, one 
calcium for each head group, leaving it as a doubly charged anion. Calcium masking the charges of the 
teichoic acids may allow for increased passage through the cell wall. More research is needed to 
conclusively answer how calcium affects the interaction of the dimer with the cell wall. 
 
Figure 2.4: Kynurenine fluorescence of dap and dap dimer on PDC 134 L-forms at 30 °C. The figure follows 
maximum normalized analog fluorescence (I442) as a function of Ca2+ concentration. 
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antibacterial activities. As with these analogs on the 70:30 PC:PG membrane, the dimer displays a 
comparatively higher fluorescence intensity response; though, on the bacterial cells the shift in response 
is not as extensive until higher calcium concentrations. As with the result on model membranes, the 
fluorescence shift may be a product of the assumed reduction in oligomerization entropy cost; once 
again, it does not correspond to the MIC of dap and the dap dimer on the L-forms. Perhaps the physical 
constraints of dimerization affect the final functionality of the pore. 
2.4 Discussion 
Characterization of the acyl-linked dimer of dap shows it is not an effective analog for the treatment of 
bacteria within dap’s known antibacterial spectrum. Dimerization altered the physical properties of dap 
sufficiently to cause sequestration within the cell wall matrix of B. subtilis to a point where activity was 
greatly diminished. Increased calcium concentration can partially rescue the analog’s activity, however, 
this is unlikely to be able to be exploited in a clinical setting as dap in vivo relies on the physiological 
calcium concentration of its host.  
The underlying principle behind the synthesis of the analog may have worked in part. The 
fluorescence intensity response of the Kyn13 fluorophore in the pre-oligomerized analog is shifted to 
comparatively lower calcium concentrations in the presence of PC/PG membranes than dap. This could 
indicate deeper membrane binding or some change in the process of oligomerization; the difference 
cannot be distinguished as the fluorescence of binding is coupled with that of oligomerization in this 
assay. To solely study oligomerization, the addition of an extrinsic fluorophore to the analog would be 
required. If a change to oligomerization did occur, this could be due to the expected reduction in the 
entropy cost of oligomer formation. Nevertheless, the change in Kyn13 response did not correspond to 
an increase in the antibacterial activity of the dimer. Even when used with wall-deficient susceptible 
bacteria, the activity was comparatively decreased to dap. The physical constraints of the dimer may 
have changed the structure of the ultimate membrane-spanning pore, by altering the conformation of 
its oligomeric components.  
The importance of the cell wall as a barrier to native dap activity was also shown. The activity of dap 
increased 10-fold on the cell-wall deficient L-form bacteria, compared to their walled N-form state. 
This clarifies why increased cell wall thickness is correlated to dap resistance – it is likely it increases 
the quantity of antibiotic sequestered.116 The presence of this significant barrier also calls into question 
the dap action mode proposed by some researchers. The action mode suggests the production of 
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micellar dap as the first step.117,118 The micelle then diffuses to the bacterial membrane and once in 
close proximity, it dissociates and dap monomers insert into the bilayer; oligomerization or 
conformational changes then occur and the cells are ultimately killed by membrane perforation. The 
formation of the micelle is supported by NMR studies which indicate a 14–16mer of dap with the 
addition of 1 molar equivalent of calcium.117,118 However, if the direct dimerization of dap causes the 
antibiotic to lose function in the presence of peptidoglycan, it is likely that the multimer described 
would not penetrate the cell wall and deliver dap to the bacterial cell membrane.  
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Chapter 3 
Characterizing synthetic analogs of daptomycin 
3.1 Introduction 
Dap analogs are a valuable tool to establish the structure-activity relationship (SAR) of dap. Altering 
the structure of the antibiotic allows for characterization of the specific role of different amino acids in 
the overall activity. Substitutions to specific amino acids may also improve properties such as 
antibacterial activity, spectrum, toxicity, and susceptibility to surfactant sequestration. There are 
multiple approaches to the synthesis of these analogs, however, only dap analogs produced through the 
solid-phase peptide synthesis (SPPS) method developed by the Taylor group will be discussed here.119 
The use of SPPS to synthesize dap is highly beneficial as the technique is conducive to the generation 
of combinatorial analog libraries. This would drastically improve the speed of discovery of significant 
analogs. However, the structure of dap poses some difficulties in the production of a library; two are 
the presence of MeGlu and Kyn residues in position 12 and 13, respectively. MeGlu of the correct 
stereochemistry is synthetically challenging and tedious to prepare in large quantities. The α-carboxylic 
acid group of kynurenine is a component in the ring-closing depsi bond of dap; kynurenine in this 
position imparts low cyclization yields during synthesis. Consequently, replacing the residues with 
amino acids which resolve the synthetic difficulties and preserve antibacterial activity would be 
advantageous. The resulting peptide could then be used as the base scaffold for library generation. 
MeGlu12 and Kyn13 have been substituted previously by other groups, both alone and in 
combination with additional changes; however, the acyl tail of the analogs was anteisoundecanoyl, 
rather than the decanoyl tail of dap.85 The substitution of the native MeGlu residue in position 12 with 
Glu (E) decreased the activity; the MIC increased nearly 16-fold.85 The substitution of the native Kyn 
residue in position 13 with Trp (W), Ile, or Val decreased the activity; the MICs increased by 2-, 4- and 
8-fold, respectively.85 The Taylor group chose to initially synthesize the double mutants dap-E12-W13 
and dap-E12-Y13 (Figure 3.1). Dap-E12-Y13 has Glu at position 12 and tyrosine (Tyr; Y) at position 
13. Subsequently, dap-A7-E12-W13 and dap-E12-Y13-pyrene were synthesized. Dap-A7-E12-W13 is 
a triple mutant with alanine (Ala, A) at position 7, in addition to E12 and W13; it was synthesized to 
help resolve differences in analog activities at high calcium. Dap-E12-Y13-pyrene attaches a pyrene 
fluorophore to the acyl tail of the aforementioned dap-E12-Y13 analog; this allows for the 
characterization of oligomerization. 
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Figure 3.1: Initial dap analogs synthesized through SPPS: dap-E12-W13, dap-E12-Y13, and dap-A7-E12-
W13. Dap-E12-W13, dap-E12-Y13 contain the native Asp (D) at position 7; dap-A7-E12-W13 contains Ala 
(green). All analogs contain Glu (E) at position 13 (blue). Dap-E12-W13 and dap-A7-E13-W13 contain Trp 
(W), and Dap-E12-Y13 contains Tyr (Y), at position 13 (red). 
Characterization of the synthesized analogs is possible through assays which indicate membrane 
binding, oligomerization, pore formation, and antibacterial activity. Membrane binding is detected in 
the presence of liposomes by calcium-dependent increases to the quantum yield of dap’s intrinsic 
Kyn13 fluorophore, or the blue-shift of A5’s intrinsic Trp1 fluorophore. The formation of oligomers is 
detected in the presence of liposomes through the calcium-dependent formations of excimers within 
pyrene-labeled dap. Pore formation is detected with a liposome permeabilization assay which displays 
pore-dependent increases in the fluorescence of liposomes loaded with a pH-sensitive dye. 
Antibacterial activity is measured through MIC assays on susceptible bacteria. 
Some of the tests can also be performed on, or in the presence of, artificial lung surfactant to test the 
analogs’ susceptibility to surfactant sequestration. These tests are important as dap performed poorly 
against pneumonia in vivo in Phase 3 clinical trials, despite high in vitro activity against S. 
pneumoniae.60,120 The low efficacy in the clinical trials likely results from an interaction with pulmonary 
surfactant, which sequesters the drug.60 If the experiments show that the dap analogs are less susceptible 
to surfactant inactivation, it could be important in devising an analog with in vivo activity against 
pneumonia. The commercial lung surfactant used here is bovine lipid extract surfactant (BLES). It 
contains 27 mg/mL of phospholipids, 176-500 µg/mL of surfactant-associated proteins B and C, and 
sodium and calcium chloride salts. The phospholipids likely contain a high percentage of PC, a low 
percentage of PG, and multiple other trace lipids as these are the lipids within characterized lung 
surfactant.121 The proteins are essential to the in vivo usage of lung surfactant.121 
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3.2 Material and Methods 
A54145 Factor D was provided by Jared Silverman (Cubist Pharmaceuticals, Inc; Lexington, MA, 
USA). The daptomycin analogs were produced through SPPS by the Taylor research group (University 
of Waterloo; Waterloo, ON.); high purity was assessed by HPLC and mass spectroscopy. 
3.2.1 Preparation of liposomes 
The procedure for the preparation of the liposomes (LUVs) has been described in a preceding chapter 
(see section 2.2.1). 
3.2.2 Fluorescence studies 
The procedure for performing the fluorescence studies has been described in a preceding chapter (see 
section 2.2.3). 
Table 3.1: Fluorophore, excitation wavelength, and emission range of relevant lipopeptide analogs. 
Lipopeptide Fluorophore Excitation (nm) Emission (nm) 
Dap Kyn13 365 400–600 
Dap-E12-W13 Trp1 / Trp13 280 300–400 
Dap-E12-Y13 Trp1 280 300–400 
Dap-E12-Y13-pyrene Pyrene 340 360–600 
Dap-A7-E12-Y13 Trp1 280 300–400 
A5 Trp1 280 300–400 
A5-pyrene Pyrene 340 360–600 
3.2.3 Determining the antibacterial activity of antibiotics 
The procedure for determining the minimum inhibitory concentration of the antibiotics has been 
described in a preceding chapter (see section 2.2.4). 
3.3 Results 
The synthetic procedure developed by Dr. Chuda Lohani from the Taylor group was first used to 
produce unsubstituted dap.89 The synthetic dap is generated through SPPS and thus designated dap-
SPPS. Part of validating the synthetic procedure was to compare the antibacterial activity and 
membrane binding characteristics of authentic dap to the synthetic dap. 
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Figure 3.2: Kynurenine fluorescence of Dap and Dap-SPPS on liposomes of varying composition at 37 °C.  
The figure follows maximum normalized analog fluorescence (I442) as a function of Ca2+ concentration. 
The antibacterial activity results at 5 mM Ca2+ are identical at an MIC of 0.75 µg/mL (Table 3.2); 
the authentic dap and dap-SPPS also show equivalent responses in fluorescence intensity on a 50:50 
PC:PG membrane, as calcium is added incrementally (Figure 3.2). These tests, in addition to HPLC 
chromatograms, mass spectroscopy and NMR, verify that the synthetic dap is equivalent to the 
authentic dap. This confirms the synthetic procedure is able to generate authentic dap and thus can 
reliably generate synthetic derivatives of dap, such as dap-E12-W13 and dap-E12-Y13. 
Table 3.2: MIC (µg/mL) assay results of various lipopeptide analogs at 5 and 100 mM Ca2+ on B. subtilis 
ATCC 1046. 
 Ca2+ Concentration 
Lipopeptide 5 mM 100 mM 
Dap 0.75 0.50 
Dap-SPPS 0.75 N/D 
Dap-E12-W13 1.5 1.5 
Dap-E12-Y13 35 1.3 
Dap-E12-Y13-pyrene >50 1.5–3.0 
A5 0.75 0.75 
A5-pyrene 0.75–1.0 N/D 
N/D = no data   
The antibacterial activities of the dap-E12-W13 and dap-E12-Y13 analogs were tested (Table 3.2). 
Compared to dap and A5, dap-E12-W13 remained highly active, while dap-E12-Y13 lost considerable 
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activity; the Trp analog MIC increased 2-fold whereas the Tyr analog MIC increased over 45-fold. The 
activity of dap-E12-W13 is sufficiently effective for use of the analog as the base scaffold for the 
synthesis of others.  
When the antibacterial activities of the analogs were tested at 100 mM Ca2+, the activity for most 
decreased, however, unexpectedly, that of dap-E12-Y13 decreased vastly in comparison to the others. 
The dap-E12-Y13 MICs decreased to just below 2.5-fold over that of dap at 100 mM Ca2+. From this 
it is assumed that the residues in position 12 and 13 have a role in the calcium affinity of dap.89 To 
investigate the functional differences between the analogs, they were characterized using fluorescence 
studies which indicate membrane binding and oligomer formation. 
3.3.1 Dap-E12-W13 and dap-E12-Y13 membrane binding 
 
Figure 3.3: Tryptophan fluorescence spectra of dap-E12-W13 and dap-E12-Y13 in the presence of 70:30 
PC:PG liposomes and increasing Ca2+ concentration (mM) at 37 °C.  
The membrane binding assay for dap exploits the intrinsic Kyn fluorophore, as this residue has been 
substituted in the analogs a different fluorophore must be used. Conveniently, the lipopeptides contain 
an additional intrinsic fluorophore, the Trp residue in position 1 (and position 13 in dap-E12-W13). 
The indication of membrane binding using Trp is the distinct blue-shift when it enters a more 
hydrophobic environment. The analogs both display a blue-shift as calcium is added incrementally, 
however, it occurs at lower calcium concentrations for dap-E12-W13 (Figure 3.3). To compare to dap 
a dual plot can be used; dap, as with the other analogs, contains a Trp residue at position 1, however, 
its Kyn residue vastly reduces its fluorescence through FRET (Figure 3.4). The dual plot follows the 
0
20
40
60
80
100
120
300 320 340 360 380 400
F
lu
o
re
s
c
e
n
c
e
 (
1
0
3
c
p
s
)
Wavelength (nm)
Dap-E12-W13 [70% PC, 30% PG] 37˚C
0
10
20
30
40
50
60
70
80
90
100
300 320 340 360 380 400
Wavelength (nm)
Dap-E12-Y13 [70% PC 30% PG] 37°C
Liposome Control
Analog Control
AnalogLiposome
Control
AnalogLiposome
+ 0.01Ca
AnalogLiposome
+ 0.05Ca
AnalogLiposome
+ 0.10Ca
AnalogLiposome
+ 0.50Ca
AnalogLiposome
+ 1.0Ca
AnalogLiposome
+ 5.0Ca
AnalogLiposome
+ 10.0Ca
AnalogLiposome
+ 50.0Ca
  47 
increase in Kyn fluorescence intensity in dap and the fluorescence blue-shift of Trp in the analogs 
(Figure 3.4). 
  
Figure 3.4: Mean tryptophan wavelength emission of dap-E12-W13 (left) and Dap-E13-Y13 (right) 
compared to maximum fluorescence intensity of dap emission (I442), each as a function of Ca2+ 
concentration.  Liposome composition is 70:30 PC:PG. 
The native dap fluorescence signal increases significantly after 0.1 mM Ca2+ and saturates around 5–
10 mM Ca2+; the midpoint of the transition occurs between 0.1 and 0.5 mM Ca2+. The dap-E12-W13 
fluorescence blue-shift progresses slowly as the calcium concentration is increased, with the most 
significant blue-shifting occurring past 0.5 mM Ca2+; its transition midpoint occurs around 1 mM Ca2+. 
Dap-E12-Y13 shows a vastly delayed response, and does not blue-shift prominently until over 1 mM 
Ca2+; its transition midpoint occurs just over 5 mM Ca2+. The order of the transition midpoints, from 
lowest to highest, is dap, dap-E12-W13, then dap-E12-Y13. This corresponds to their respective MICs 
at 5 mM Ca2+, which are 0.75, 1.5 and 35 µg/mL. 
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Figure 3.5: Tryptophan fluorescence spectrum of A5 in the presence of 70:30 PC:PG liposomes and 
increasing Ca2+ concentration (mM) at 37 °C. 
As an alternative to the dual plots, direct comparison of the analogs to A5, whose Trp residue is free 
from quenching, is possible (Figure 3.5). The comparison remains informative, as A5 has an identical 
MIC to dap and it has been shown to be functionally closely related – dap and A5 are able to form 
partially functional hybrid oligomers.78 Following the blue shift of A5 and the dap analogs is possible 
by plotting the ratio of emission at 333 nm to that at 354 nm as a function of calcium – the ratio will 
increase as the blue-shift progresses (Figure 3.6). 
  
Figure 3.6: Tryptophan fluorescence of A5, dap-E12-W13, dap-E12-Y13 on liposomes of varying 
composition at 37 °C. The figure follows the fluorescence blue-shift (I333/I354) as a function of Ca2+ 
concentration.  
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A5 begins its blue-shift at calcium concentrations over 0.5 mM on 70:30 PC:PG; of the analogs, dap-
E12-W13, is the most similar. Its blue-shift also begins at calcium concentrations over 0.5 mM, but it 
is less pronounced. The transition midpoint for both occurs in the region above 1.0 mM, but below 5 
mM Ca2+. Dap-E12-Y13 shows a delayed response, and does not blue-shift prominently until over 1 
mM Ca2+; the transition midpoint remains around 5 mM Ca2+. As with dap, these results mostly 
correspond with the MIC results; the transition midpoints of A5 and dap-E12-W13 are comparable, yet 
the MIC of the analog is higher – this difference may be reflected in the less pronounced blue-shift. 
3.3.2 Dap-E12-Y13 oligomer formation 
 
Figure 3.7: Pyrene fluorescence spectrum of A5-pyrene in the presence of 50:50 PC:PG liposomes and 
increasing Ca2+ concentration (mM) at 37 °C. Legend: A5P and A5PLip refer to A5-pyrene alone or in the 
presence of liposomes, respectively. 
Perylene and pyrene fluorophores have been used previously to characterize the oligomerization of 
dap and A5, respectively (Figure 3.7).75 This was accomplished through the detection of excimers at 
calcium concentrations known to promote oligomer formation. Excimers, or excited dimers, are 
complexes that form from the direct contact of a fluorophore molecule in the excited state with another 
in the ground state. The fluorophore is within the acyl tail of the analogs, consequently, excimer 
fluorescence indicates that the acyl tails of nearby oligomer subunits are in immediate contact with one 
another. 
Oligomerization is known to be a necessary but not sufficient condition for pore formation, the end 
result required for antibacterial activity.52,78 Therefore, if oligomer formation is shifted to higher 
calcium concentrations, you can assume its antibacterial response is shifted as well. Characterizing the 
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excimer formation of dap-E12-Y13-pyrene over a wide calcium concentration range will indicate 
whether oligomerization is shifted, and consequently its requirement of high calcium for antibacterial 
activity is appropriate. The pyrene spectrum is composed of monomer peaks from 360–440 nm and an 
excimer peak above 440 nm.122 For easy comparison of analogs it is possible to find the ratio of the 
excimer fluorescence at 471 nm and the monomer fluorescence at 378 nm (extent of excimer formation) 
as a function of calcium (Figure 3.8). 
 
Figure 3.8: Excimer formation comparison of A5-pyrene and dap-E12-Y13-pyrene on liposomes of varying 
composition at 37 °C. The figure follows the extent of excimer formation (I471/I378) as a function of Ca2+ 
concentration.  
The spectrum of dap-E12-Y13-pyrene shows both weak and shifted excimer formation compared to 
A5-pyrene. A5-pyrene excimers begin forming after 0.1 mM Ca2+ on the 50:50 PC:PG membrane; by 
5 mM Ca2+ the extent of excimer formation is high. This corresponds to its low 0.75 µg/mL MIC. Dap-
E12-Y13-pyrene excimers begin forming after 1 mM Ca2+ concentration; by 5 mM Ca2+ the extent of 
excimer formation remains very low. Again, this corresponds to its high >50 µg/mL MIC. At 100 mM 
Ca2+, the extent of excimer formation of dap-E12-Y13-pyrene has increased and it shows a 
correspondingly increased antibacterial effect, with an MIC of 1.5–3.0 µg/mL. The shift of dap-E12-
Y13 antibacterial activity to higher calcium concentration of appears to be appropriate considering its 
comparably shifted excimer fluorescence. 
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3.3.3 Dap-A7-E12-W13 antibacterial activity and membrane binding 
 
Figure 3.9: Fluorescence spectrum of dap-A7-E12-W13 in the presence of 50:30 PC:PG liposomes and 
increasing Ca2+ concentration (mM) at 37 °C. Legend: DapAEW and DapAEWLip refer to dap-A7-E12-
W13 alone or in the presence of liposomes, respectively. 
Dap-A7-E12-W13 has a substitution to the conserved lipopeptide aspartic acid residue at position 7. 
Substitutions to this position have been shown previously to lack antibacterial activity; although that 
particular analog was a triple mutant, with substitutions to positions 2 and 12 as well.123 This analog 
was synthesized to show that the bacteria in the antibacterial activity assays were not being adversely 
affected by high calcium concentration and dying in a fashion non-specific to dap’s mechanism of 
action. Ultimately, the control worked as the MIC for dap-A7-E12-W13 on B. subtilis 1046 was over 
100 µg/mL for both 5 and 100 mM Ca2+ (Table 3.4).119 The MIC on L-forms was also determined to 
indicate whether use of this strain increases the activity of all analogs; the MIC remained over 60 µg/mL 
at 5 mM Ca2+.  The high MICs corresponds to the membrane binding data, which shows no blue-shift 
up to a calcium concentration of 200 mM (Figure 3.9).  
3.3.4 Dap-E12-W13 surfactant sequestration 
Lastly, the antibacterial activity of dap-E12-W13 in the presence of the bovine lung extract surfactant 
(BLES) was determined; comparison is to the results of dap and A5 in identical conditions. Dap-E12-
Y13 was excluded due to its low activity. To emulate physiological conditions, 1 mM rather than 5 mM 
Ca2+ was used (Table 3.3).67 
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Table 3.3: MIC (µg/mL) of lipopeptides in the absence and presence of lung surfactant on B. subtilis ATCC 
1046. 
Lipopeptide  
(or antibiotic) 
B. subtilis ATCC 1046 
 0% BLES 1% BLES 
Dapa 2 >40 
Dap-E12-W13a >12 >45 
A5a 4 30 
Ceftriaxone 0.5 0.5 
a1 mM Ca2+   
 Dap and A5 have MICs over 2.5- and 5-fold higher than at 5 mM Ca2+; dap-E12-W13’s increased 
by a minimum of 8-fold. When in the presence of surfactant dap and dap-E12-W13 have MICs over 40 
µg/mL; A5 has an MIC of 30 µg/mL. The antibacterial activity of A5 is therefore more affected by the 
decrease in calcium concentration than dap, however, its activity in the presence of surfactant is less 
inhibited. The activity of dap-E12-W13 is most inhibited by the decrease in calcium concentration, and 
the amino acid substitutions appears not to reduce the sequestration of the antibiotic into surfactant. As 
a control, ceftriaxone, a β-lactam antibiotic, is used. It confirms that not all antibiotics lose activity in 
the presence of surfactant. 
  
Figure 3.10: Comparison of dap (left) and A5 (right) on PC/PG liposomes and 1% surfactant. The figures 
follow the fluorescence intensity (left: I442) and the fluorescence blue-shift (right: I336/354), as a function of 
Ca2+ concentration. 
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The binding of the lipopeptides to BLES was characterized using the same procedure as membrane 
binding, however the liposomes were exchanged for surfactant. Dap binds to surfactant in a manner 
comparable to 50:50 PC:PG liposomes, the fluorescence intensity is nearly identical as calcium is added 
incrementally (left: Figure 3.10). The transition midpoint for both occurs between 0.1 and 0.5 mM Ca2+. 
A5 binds to surfactant less than to 50:50 PC:PG liposomes, its fluorescence blue-shift requires higher 
calcium concentrations (right: Figure 3.10). The transition midpoint shifts from 0.5 mM to over 1 mM 
Ca2+. Less binding to surfactant leaves a higher proportion of antibiotic free to interact with bacterial 
cells, therefore, the binding results agree with the respective antibacterial activity of dap and A5 in the 
presence of surfactant. 
 
Figure 3.11: Comparison of dap-E12-W13 on PC/PG liposomes and 1% surfactant. Fluorescence intensity 
(I336) is followed as a function of Ca2+ concentration. 
Dap-E12-W13 on surfactant reflects a binding pattern most similar to that of dap; the midpoint of 
the transition appears to be shifted very slightly to the right, if at all (Figure 3.11). The amino acid 
substitutions consequently appear have little or no change to the sequestration of the lipopeptide into 
surfactant. However, the substitutions do cause the activity of the analog to be significantly decreased 
at 1 mM Ca2+. 
3.4 Discussion 
Characterization of the initial synthetic dap analogs produced by the Taylor group reveals dap-E12-
W13 as the most notable; its antibacterial activity approaches that of dap and A5, at only double the 
MIC. The synthesis and partial characterization of these analogs was published by Lohani et al.89,119 
The high antibacterial activity and simplified synthetic procedure of dap-E12-W13 make it a viable 
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candidate for the role as the base scaffold in the generation of a combinatorial analog library. 
Nevertheless, the analog does not exhibit significantly increased tolerance to the presence of surfactant, 
and at physiological calcium concentrations the antibacterial activity is comparatively decreased to dap 
and A5. 
Dap-E12-W13 is amongst the most active dap analogs characterized by research groups in this 
field.124 Table 3.4 displays the antibacterial activities of dap analogs below 10 times that of the native 
dap, with the exception of the single substitution variants of dap-E12-W13 and dap-E12-Y13. Over 
twenty additional dap analogs with differing amino acids substitutions have been characterized.124 The 
significant antibacterial activity of dap-E12-W13 is unexpected considering the two amino acid 
substitution were performed previously and separately yielded an increase in MIC by 2-fold and nearly 
16-fold for Trp and Glu, respectively.85 Whether the substitutions function better together, or the change 
to a decanoyl tail altered the analog’s activity considerably has not been established; however, 
A21978C1, a dap derivative with an anteisoundecanoyl tail, has exhibited lower in vivo activity against 
S. aureus and Streptococcus pyogenes.57 
The dap-E12-Y13 analog is on the other end of the spectrum; its antibacterial activity is low. 
Changing the amino acids at position 12 and 13 may change the geometry of the lipopeptide, making 
the calcium affinity lower – the defect would be greater with some amino acids, consequently they 
require higher calcium concentrations to induce calcium binding and the successive membrane 
association and oligomerization. Dap-A7-E12-W13 is inactive, as expected, and its effect is not rescued 
by high calcium as the native Asp residue in position 7 likely directly binds to calcium. 
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Table 3.4: Antibacterial activities of select dap analogs produced by different groups. Only relevant amino 
acid positions are listed. MIC ratio refers to the MIC of the analog divided by the MIC of native dap. 
Lipopeptide Amino acid position MIC Ratio 
 1 8 11 12 13  
Dap Trp D-Ala D-Ser MeGlu Kyn 1 
185    Glu  16 
285     Trp 2 
389    Glu Trp 2 
489    Glu Tyr 47 
585   D-Ala   2 
685  D-Lys D-Asn   2 
785   D-Asn  Ille 8 
887 Phe     4 
985  D-Ser    2 
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Chapter 4 
Characterizing lysyl-phosphatidylglycerol-mediated daptomycin 
resistance 
4.1 Introduction 
Resistance, or non-susceptibility, to dap has been correlated in part to changes in the mprF gene.125,126 
mprF codes for the multiple peptide resistance factor (MprF) enzyme, which catalyzes the synthesis of 
LPG from PG; it is also the flippase which moves LPG from the inner membrane leaflet to the outer 
membrane leaflet.96 The relevance of the changes has been corroborated by the detection of similar 
mutations in clinical isolates of S. aureus which have developed treatment-emergent increases to the 
dap MIC.51  
LPG-mediated dap resistance has yet to be comprehensively studied; due to its clinical significance, 
it is an important topic of research. Characterization of the mechanism of resistance could yield 
information which allows for the production of dap analogs with decreased non-susceptibility. A 
potential mechanism of resistance is available as MprF gain-of-function mutants are also associated to 
bacterial resistance to cationic antimicrobial peptides (CAMPs).127 CAMPs include some host defense 
peptides (HDPs), which are part of the innate immune response in humans.98 In fact, bacteria with 
treatment-emergent non-susceptibility to dap can develop cross-resistance to HDPs; this provides a 
distinct survival advantage to the bacteria in bloodstream infections.98,128 
The proposed mechanism through which MprF gain-of-function mutants gain resistance to CAMPs 
is a decrease in the membrane binding of the peptides to the bacterial membrane.96 This arises due to 
electrostatic repulsion between the cationic peptides and the increased positive charge in the membrane; 
the addition of lysine to PG changes the net charge of the membrane lipid from −1 to +1. For this 
mechanism to occur with dap, it must be presumed that in conjunction with calcium the lipopeptide is 
acting in a CAMP-like manner and has its membrane association reduced. At physiological pH, dap 
has a net charge of −3; consequently, two calcium ions binding to dap in solution would be required to 
cause a reversal of charge. NMR studies of dap in solution have indicated that calcium binds to dap in 
solution with a 1:1 stoichiometry.82,83 This would leave dap in solution as a singly-charged anion, 
bringing question to whether this mechanism is correct. An alternative mechanism has been shown with 
at least one cationic peptide; rather than reducing association with the membrane, an attenuation of 
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membrane perturbation decreased peptide-induced membrane permeabilization.97 As peptide charge is 
not a main factor, this mechanism may be more likely for dap. 
Characterization of the mechanism of LPG-mediated dap resistance is possible through assays which 
indicate whether the successive steps of the action mode of dap are occuring.52,75,84 The steps include, 
(1) calcium-mediated binding to PG at the outer leaflet; (2) formation of oligomers; (3) formation of 
pores through equilibration and alignment of oligomers across both membrane leaflets. Membrane 
binding can be detected in the presence of liposomes through calcium-dependent increases to the 
quantum yield of dap’s intrinsic Kyn13 fluorophore, or the blue-shift of A5’s intrinsic Trp1 
fluorophore. The formation of oligomers is detected in the presence of liposomes through the calcium-
dependent formations of excimers within pyrene-labeled A5. Translocation can be detected through the 
self-quenching of acrylodan-labeled A5. Pore formation is detected with a liposome permeabilization 
assay which displays pore-dependent increases in the fluorescence of liposomes loaded with a pH-
sensitive dye. 
4.2 Materials and Methods 
Gel filtration procedures are done on a Bio-Rad P-6DG column (Bio-Rad, Richmond, CA, USA). 
4.2.1 Preparation of liposomes 
The procedure for the preparation of the liposomes (LUVs) has been described in a preceding chapter 
(see section 2.2.1) 
4.2.2 Fluorescence Studies 
The procedure for performing the fluorescence studies has been described in a preceding chapter (see 
section 2.2.3)  
Table 4.1: Fluorophore, excitation wavelength, and emission range of relevant lipopeptide analogs. 
Lipopeptide Fluorophore Excitation (nm) Emission (nm) 
Dap Kyn13 365 400–600 
A5 Trp1 280 300–400 
A5-acrylodan Acrylodan 360 400–600 
A5-pyrene Pyrene 340 360–600 
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4.2.3 Measurement of membrane permeabilization with pyranine-loaded liposomes 
Liposomes of a given lipid composition are prepared as described previously. The hydration buffer 
consists of pyranine (5 mM) in a MES/Tricine (5 mM, pH 6.0), NaCl (5 mM), KCl (5 mM), and sucrose 
(250 mM) solution. After hydration and membrane extrusion, the mixture is passed through a gel 
filtration column to remove un-encapsulated pyranine; gel filtration may be repeated as required. The 
fluorescence assay samples contain a total lipid concentration of 250 µM, 5 nM CCCP, and a final 
concentration of 0.5 µM of lipopeptide analog. The assay buffer is identical to the hydration buffer, 
except for an increase in pH to 8.0, and a NaCl or KCl concentration of 100 mM. Calcium is added to 
a concentration of 5 or 100 mM to start the assay. For pyranine, the excitation wavelength is 460 nm, 
and the emission wavelength is 510 nm. The fluorescence time curve is recorded over 300 seconds, 
after which Triton X-100 is added to a final concentration of 0.1% to solubilize the liposomes. The 
spectrum is recorded for an additional 60 seconds to establish the fluorescence intensity equivalent to 
100% test solute equilibration. Controls involve measurements of the liposomes alone, and the 
liposomes in the presence of the lipopeptide, calcium, Triton X-100, and CCCP, separately. 
4.3 Results 
The chosen base membrane composition was 70:30 PC:PG. It represents a simple dap-sensitive 
membrane; PG is required for the action mode of dap, while PC is a mostly inert lipid with respect to 
dap at low calcium concentrations. The initial LPG-containing membranes were 55:30:15 PC:PG:LPG 
and 70:30 PC:LPG; others were planned, however, LPG research was discontinued due to its 
prohibitive cost, and initial attempts at its synthesis failed. In the membrane including both PG and 
LPG, the PG content was kept constant. This was done to distinguish the potential specific inhibitory 
effect of LPG from that of a diminished amount of PG; in bacterial membranes, the inhibitory role of 
each is not distinguished – upregulation of LPG synthesis requires increased use of its precursors, which 
include PG. For simplicity, hereafter, the membrane containing PC, PG, and LPG will be designated 
the ‘hybrid LPG’ membrane, and the membrane containing PC and LPG will be designated the ‘pure 
LPG’ membrane. 
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Figure 4.1: Kynurenine fluorescence of dap on liposomes of varying composition at 37 °C; the exception is 
the 55% PC, 30% PG, 15% LPG membrane under ambient conditions (~25 °C).  The figure follows 
maximum normalized analog fluorescence (I442) as a function of Ca2+ concentration.  
The results for the dap membrane binding assay using the LPG-containing membranes are intriguing 
(Figure 4.1). Dap on the hybrid LPG membrane displays a shifted calcium-dependent fluorescence 
intensity response compared to the 70:30 PC:PG membrane; at lower calcium concentrations the 
increase in intensity is greater. This could indicate an enhanced interaction with the membrane, such as 
deeper insertion. If the mechanism of dap resistance is mediated by reduced membrane association, the 
opposite of this result should occur. Even if 15% LPG in the membrane is not sufficient for high-level 
dap resistance, the fluorescence intensity response should simply not shift. The cause of the shift has 
not been established; more membranes with LPG in the presence of PG are needed. Whether the 
enhanced interaction reverses at higher LPG concentrations, is not known. 
Dap on the pure LPG membrane shows the opposite result; compared to the base membrane, 
increased calcium is required to get dap to bind to the membrane. This is expected as PG is required 
for dap to bind to membranes at low calcium concentration. However, in comparison to the PC 
membrane, the fluorescence intensity of dap increases at a lower calcium concentration; consequently, 
it appears that dap can use LPG in place of PG at high calcium concentrations. Moreover, it shows that 
electrostatic repulsion is not a factor in dap binding. The membrane is entirely composed of neutral or 
positively charged lipids, therefore if dap was repulsed it would bind at higher calcium concentrations 
compared to the PC membrane. 
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Figure 4.2: Tryptophan fluorescence of A5 on liposomes of varying composition at 37 °C; the exception is 
the 55% PC, 30% PG, 15% LPG membrane under ambient conditions (~25 °C).  The figure follows the 
fluorescence blue-shift (I333/I354) as a function of Ca2+ concentration.  
The results for A5 correspond closely to those of dap (Figure 4.2). A5 fluorescence on the hybrid 
LPG membrane undergoes a blue-shift at a lower calcium concentration. The calcium-binding of A5 in 
solution has not been studied through NMR, however, it likely binds calcium in the same manner as 
dap, thus its results are similar (A5 and dap share the same net charge at physiological pH, −3). The 
pure LPG membrane delays the fluorescence blue-shift until over 5 mM Ca2+ has been added, whereas 
a blue-shift does not occur on the PC membrane. The difference between A5 on the LPG and PC 
membranes is thus greater than that seen with dap, however the membrane binding begins at over 5 
mM Ca2+ compared to 1 mM Ca2+ for dap. This may be due to the intrinsic differences between the two 
lipopeptides, or the location of the intrinsic fluorophore (Trp1, exocyclic tripeptide; Kyn13, head group) 
– in either case, it reaffirms that LPG within the membrane promotes some membrane binding at high 
calcium concentrations. 
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Figure 4.3: Excimer formation comparison of A5-pyrene on liposomes of varying composition at 37 °C; the 
exception is the 55% PC, 30% PG, 15% LPG membrane under ambient conditions (~25 °C). The figure 
follows the extent of excimer formation (I471/I378) as a function of Ca2+ concentration. 
Despite the fact that the dap and A5 are binding to the LPG-containing membranes, the subsequent 
steps necessary for antibacterial activity, namely oligomerization and pore formation, may not be 
occurring. To test for the occurrence of oligomerization, A5-pyrene was used (Figure 4.3). Pyrene 
excimers begin forming around 0.10, 0.25, and 5 mM Ca2+ on the hybrid LPG, 70:30 PC:PG, and pure 
LPG membranes, respectively; the formation continues until saturation at approximately 0.5, 5 and 60 
mM Ca2+. The graph displays the extent of excimer formation continuing past the point of saturation 
on the 70:30 PC:PG membrane and LPG membrane, however, this occurs due to a decrease in monomer 
fluorescence intensity, with little or no associated excimer fluorescence – detailed fluorescence lifetime 
studies might resolve the disparity (see appendix: Figure 6.16, Figure 6.20). 
The presence of excimers on all the membranes confirms that oligomerization is occurring. The 
calcium concentrations required to induce excimer formation follow the previously established pattern 
and resembles those required to induce kynurenine fluorescence on the respective membranes. Most 
surprising is the formation of oligomers on the pure LPG membrane, as excimers do not form on PC 
membranes (data not shown). This shows that despite LPG being correlated to resistance it is able to 
mediate both the binding dap monomers and the formation of dap oligomers in the absence of PG. 
Nevertheless, oligomerization is necessary but not sufficient for antibacterial activity, and significant 
formation only begins at calcium concentrations above physiological levels.52,78 Whether the addition 
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of some PG to this membrane could lower the required calcium concentration is not known – but seems 
likely in light of the hybrid LPG membrane.  
 
Figure 4.4: Fluorescence spectrum of A5-acrylodan in the presence of 70:30 PC:PG liposomes and 
increasing Ca2+ concentration (mM) at 37 °C. A5A and A5ALip refer to A5-acrylodan alone or in the 
presence of liposomes. 
To support the oligomerization data from A5-pyrene, A5-acrylodan was used. A5-acrylodan is an 
alternative to NBD-dap, which was used previously by the Palmer group to characterize the 
oligomerization of dap by fluorescence self-quenching.73 Recently, data from A5-acrylodan interacting 
on CL-containing liposomes has shown that that the self-quenching occurs due to translocation and 
alignments of oligomers, rather than oligomer formation. The fluorescence spectrum of A5-acrylodan 
on 70:30 PC:PG liposomes can be seen in Figure 4.4 (see appendix for other membranes; Figure 6.15, 
Figure 6.19). The initial rapid blue-shift and increase in acrylodan fluorescence coincides with in the 
binding of one calcium ion to the analog; the maximum fluorescence occurs at 0.5 mM Ca2+.84 Excimer 
formation is also seen at these calcium concentrations (see above), indicating an oligomer is forming. 
Increased calcium concentration induces the binding of a second calcium ion and acrylodan 
fluorescence begins to self-quench, indicating the translocation and alignment of oligomers. A 
functional pore is likely occurring at this point. To compare between membranes, plotting maximum 
normalized analog fluorescence as a function of calcium greatly simplifies the spectrum (Figure 4.5). 
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Figure 4.5: Acrylodan fluorescence of A5-acrylodan on liposomes of varying composition at 37 °C; the 
exception is the 55% PC, 30% PG, 15% LPG membrane under ambient conditions (~25 °C).  The figure 
follows the maximum normalized analog fluorescence (I472) as a function of Ca2+ concentration. 
The fluorescence spectrum of A5-acrylodan on the hybrid LPG membrane resembles that of the 
analog on the 70:30 PC:PG membrane; fluorescence increases with calcium at a slightly faster rate but 
reaches its maximum at the same value, 0.5 mM Ca2+. As calcium continues to increase, self-quenching 
begins as the oligomers equilibrate and align across the membrane; however, the quenching occurs to 
a lesser degree. This indicates that the translocation of oligomers may be impaired in some fashion at 
this LPG concentration – though the majority of oligomers likely still create functional pores. 
The pure LPG membrane exhibits different results. The first stage of the A5-acrylodan spectrum, the 
blue-shift and fluorescence increase, is seen – despite its need for drastically increased calcium. 
Therefore, the analog is interacting with the membrane; the formations of excimers also demonstrates 
that oligomerization is occurring at this point. In contrast, A5-acrylodan on the PC membrane shows 
acrylodan fluorescence increase at high calcium concentrations, but does not exhibit excimer formation. 
The second stage of the A5-acrylodan spectrum, the self-quenching, is the significant difference. A5-
acrylodan on the pure LPG membrane displays a complete loss of self-quenching, even at high calcium 
concentrations. This indicates that the oligomers forming on the outer membrane leaflet are not 
undergoing translocation and alignment to form a pore. This is reminiscent of CL-mediated resistance, 
in which dap can bind and form oligomers on the membrane, but translocation is inhibited and thus 
pore formation as well.52 The pure LPG membrane is of course not the most accurate model due to its 
lack of PG – nevertheless, the hybrid LPG membrane appears to be presenting the beginning of the 
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same inhibitory effect. This provides evidence that LPG-mediated resistance does not occur through a 
reduction of membrane association, rather the translocation of the lipopeptide oligomers may be 
inhibited. 
 
Figure 4.6: Liposome permeabilization tests using 0.5 uM of multiple lipopeptide analogs in the presence 
of pyranine-loading liposomes, 5 (or 100) mM Ca2+ and 5 nM CCCP at 25 °C. Controls include lipopeptide 
alone or in the presence of either Ca2+ or CCCP (see appendix). Fluorescence (I510) is normalized to the 
highest signal after Triton-X at 300s. 
Lastly, the hybrid LPG membrane was used in the liposome permeabilization assay. Within the assay, 
the production of a functional pore by an applied analog will cause the liposome interior to increase in 
pH if a proton carrier such as CCCP is also present. The increase in pH is followed by the pH-sensitive 
fluorescent dye pyranine loaded into the liposomes.  The membrane binding assays and oligomerization 
assays using dap and A5 analogs on the hybrid LPG membrane showed results similar to those of the 
analogs on 70:30 PC:PG membrane – the only difference of note is the reduced self-quenching of A5-
acrylodan. Pore formation is therefore expected to occur; the results show that dap and A5 are able to 
permeabilize the membrane (Figure 4.6). Dap caused the highest increase in fluorescence during the 
experiment time-scale, however, A5 showed the quickest initial rate of fluorescence increase. This 
might reflect the intrinsic differences between the two lipopeptides. 
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4.4 Discussion 
The preliminary results for dap on the LPG-containing membranes are insufficient for a full 
characterization of the specific inhibitory effect of LPG. Full characterization would likely require the 
examination of dap and its analogs on liposome compositions which include upwards of 30–40% LPG 
in the presence of PG. The LPG range required is high because many dap-susceptible bacteria have 
been shown to have high percentages of LPG within their membrane. A study on the phospholipid 
composition of dap-naïve B. subtilis showed a total LPG concentration of 22%.129 Clinical isolates of 
S. aureus have also been determined to contain up to a total of 30% LPG.97  
Furthermore, LPG-mediated CAMP and dap resistance have been shown to be dependent upon the 
exposure of LPG to the outer surface of the bacterial membrane, not only its increased synthesis.96 Dap 
resistance in two non-susceptible S. aureus strains showed they did not have significantly increased 
LPG concentrations compared to the parent strain (23–29%), but LPG translocation to the outer leaflets 
was 2-fold higher.8 Increased outer leaflet exposure of a set concentration of LPG is unable to be 
reproduced in a model membrane system; LPG used in the preparation of the liposomes partitions 
equally in the inner and outer leaflets, this essentially halves the concentration of LPG initially 
interacting with dap.  
Once the specific inhibitory effect of LPG has been studied, to finalize the characterization, the effect 
of the step-wise reduction of PG on a set concentration of LPG can be examined. At commercial cost, 
the need for such quantities of LPG is cost prohibitive, this is also compounded the instability of LPG 
within the prepared liposomes. Liposomes containing LPG must be prepared and used immediately. 
Results obtained over multiple days are not reproducible; as time progresses, the LPG membranes 
display results similar to those without LPG. This may be due to non-specific hydrolysis of lysine from 
the PG. 
Overall, the results for the two LPG membranes are interesting. Incorporation of 15% LPG within a 
PC/PG membrane seems to enhance the interaction of dap and A5 with the membrane. Subsequent 
oligomerization continues to occur, but oligomer translocation may be slightly inhibited. Ultimately, 
pore formation occurs and permeabilizes the membrane. Incorporation of 30% LPG within a PC 
membrane vastly reduces the interaction of dap and A5 with the membrane. Surprisingly, subsequent 
oligomerization occurs – though at non-physiological calcium concentrations. Oligomer translocation 
is completely inhibited; thus, pore formation is also inhibited. To corroborate the oligomer translocation 
data another test, such the dithionite quenching assay discussed in section 1.2.4, should be used. 
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This pattern of inhibition is reminiscent of CL-mediated resistance. CL does not prevent the 
formation of dap oligomers, but the translocation of oligomers is inhibited by stabilizing the liposome 
bilayer. A membrane stabilization effect between LPG and PG could account for slightly inhibited 
oligomer translocation on hybrid LPG membrane; stabilization may also allow for deeper insertion of 
dap into the membrane, changing its calcium-dependent fluorescence response. While the data shown 
here is preliminary, it is important to note that Kilelee et al.97 proposed a membrane stabilization process 
in LPG-mediated resistance to 6W-RP-1, a structurally unrelated cationic peptide. The group found that 
6W-RP-1 surface association with the target membrane varied only slightly with an LPG content 
between 0–30%. In contrast, the inclusion of increasing amounts of LPG inhibited the permeabilization 
of liposomes: 20% decreased both the extent and rate of fluorescent dye leakage, and 30% essentially 
eliminated leakage. Notably, the PG content was not kept constant within their experiments – LPG was 
directly substituted for PG.  
In contrast, a stabilization effect is not possible between LPG and PG on the pure LPG membrane. 
The self-quenching must then be inhibited in some other manner. The most straightforward is the lack 
of un-derivatized PG, which has long been known to be needed for the action mode of dap; however, 
the two preceding steps of the action mode have been shown to occur here. As an alternative, LPG may 
replace a calcium ion, or block the binding of a calcium ion to the peptide in some other way – this is 
conceivable as the self-quenching of A5-acrylodan has been shown to coincide with the binding of a 
second calcium ion to the peptide.84 
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Chapter 5 
Investigating the role of phosphatidylserine in daptomycin-induced 
toxicity 
5.1 Introduction 
Dap-induced toxicity is characterized foremost by myopathy.130 Myopathy manifests itself as muscle 
aching or muscle weakness in conjunction with increases in creatine phosphokinase (CPK) values in 
the blood.130 CPK is an abundant soluble enzyme found within heart and skeletal muscle cells; high 
CPK values indicate damage to the muscle tissue and cellular leakage of the muscle constituents.131 
Additional adverse reactions include pneumonia, diarrhea, headache, dizziness, rash, low blood 
pressure, shortness of breath, and abnormal liver function tests.130  
The mechanism through which dap induces muscle toxicity has not been established. Interaction with 
eukaryotic cells is possible, however, dap is known to require PG to efficiently perform its mechanism 
of action at physiological calcium concentrations (1–1.5 mM Ca2+); PG is only present in eukaryotic 
cells at around 1% of the total lipid composition, and this is mostly in the mitochondrial 
membranes.67,132 Binding of dap to mitochondrial membranes is possible, however, in bacteria dap has 
been shown not to extensively infiltrate the cytoplasm of cells.114 Therefore, if dap does to bind 
eukaryotic cells a different lipid or membrane protein must mediate the interaction. 
 
Figure 5.1: Structure of dimyristoyl phosphatidylserine. Phosphatidylserine is a major anionic 
phospholipid in eukaryotic cells.  
This research is to study whether phosphatidylserine (PS) is such a component. PS is an anionic 
phospholipid and would mediate the binding of dap to mammalian cell membranes by emulating 
bacterial PG. PS is an essential phospholipid in mammalian cells and composes 3–10% of the total 
phospholipids.133 However, most is confined to the inner cell membrane leaflet as displaying PS on the 
surface cellular membranes can trigger cell destruction by macrophages.134 Consequently, a substantial 
interaction between PS-containing membranes and dap would be required at physiological calcium 
  68 
concentrations to have implications in dap-induced toxicity in humans. The potential interaction can be 
examined via the same fluorescence assays as dap with LPG-containing membranes, as described 
above. In this case, the success or failure of the assays on PS membranes gives insight into the extent 
of dap’s interaction with the membrane. Whether full permeabilization of the membranes would be 
needed for toxicity or simple membrane binding would suffice is not known. 
5.2 Materials and Methods 
The daptomycin analogs were produced semi-synthetically by the Taylor research group (University of 
Waterloo; Waterloo, ON.); high purity was assessed by HPLC and mass spectroscopy. 
5.2.1 Preparation of liposomes 
The procedure for the preparation of the liposomes (LUVs) has been described in a preceding chapter 
(see section 2.2.1) 
5.2.2 Fluorescence studies 
The procedure for performing the fluorescence studies has been described in a preceding chapter (see 
section 2.2.3) 
Table 5.1: Fluorophore, excitation wavelength, and emission range of relevant lipopeptide analogs. 
Lipopeptide Fluorophore Excitation (nm) Emission (nm) 
Dap Kyn13 365 400–600 
NBD-dap NBD 475 500–600 
Dap-perylene Perylene 430 440–530 
A5 Trp1 280 300–400 
A5-acrylodan Acrylodan 360 400–600 
A5-pyrene Pyrene 340 360–600 
5.3 Results 
As with the LPG studies, the chosen base membrane composition was 70:30 PC:PG. It represents a 
simple dap-sensitive membrane; PG is required for the action mode of dap, while PC – despite being a 
major lipid in eukaryotic membranes – is mostly inert with respect to dap at low calcium concentrations. 
The initial PS-containing membrane was 70:30 PC:PS. For simplicity, the 70:30 PC:PS will be called 
the ‘PS’ membrane. 
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Figure 5.2: Kynurenine fluorescence of dap on liposomes of varying composition at 37 °C. The figure 
follows maximum normalized analog fluorescence (I442) as a function of Ca2+ concentration. 
Dap on the PS membrane displays a shifted calcium-dependent fluorescence intensity response 
compared to the 70:30 PC:PG membrane; higher calcium concentrations are required to increase 
intensity (Figure 5.2). In fact, the necessary calcium concentrations are only slightly below those of dap 
on the PC membrane, which is known to be relatively inert. Kyn fluorescence indicates the beginning 
of PS- and PC-mediated membrane association starts at calcium concentrations over 1 mM; therefore, 
any significant dap insertion does not coincide with physiological calcium concentrations. 
Consequently, it is unlikely that PS is involved in mediating dap-induced toxicity in vivo. 
 
Figure 5.3: Comparison of NBD-dap (left) and dap-perylene (right) on a 70:30 PC:PS membrane at 37 °C. 
The figures follows the maximum normalized fluorescence (left: I536) and the extent of excimer formation 
(right: I521/I482), as a function of Ca2+ concentration. 
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NBD-dap and dap-perylene were used to investigate any further interaction of dap residues with the 
PS membrane. NBD-dap displays no major difference in fluorescence across the calcium 
concentrations, consequently, the labeled Orn6 residue is not inserting into the membrane (left: Figure 
5.3). Dap-perylene exhibits no excimer formation, therefore, no oligomerization is occurring (right: 
Figure 5.3). In the absence of excimer formation, the Kyn fluorescence observed at calcium 
concentrations over 1 mM is likely due to the association of dap monomers with the membrane. On 
susceptible membranes, the environmentally sensitive fluorophore attached to Orn6 typically responds 
prior to Kyn if membrane binding is present – in this case, NBD exhibited no fluorescence.84 Overall, 
the results corroborate that dap has no significant association with PS membranes at physiological 
calcium concentrations, and PS is therefore unrelated to dap-induced toxicity in vivo. 
 
Figure 5.4: : Tryptophan fluorescence of A5 on liposomes of varying composition at 37 °C. The figure 
follows the fluorescence blue-shift (I333/I354) as a function of Ca2+ concentration. 
A5 does not display any fluorescence blue-shift on PC or PS membranes; consequently, the Trp 
residue of A5 does not associate with the membrane (Figure 5.4). A5 is more toxic in mouse models of 
toxicity than dap; therefore, if PS was a deciding factor in toxicity, an increased interaction  of A5 with 
PS-containing membranes would be expected.64 This is not demonstrated in the Trp results, however 
other A5 residues may interact with the membrane. 
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Figure 5.5: Comparison of A5-acrylodan (left) and A5-pyrene (right) on liposomes of varying composition 
at 37 °C. The figures follows the maximum normalized fluorescence (left: I472) and the extent of excimer 
formation (right: I471/I378), as a function of Ca2+ concentration. 
On the PS membrane, the fluorescence of A5-acrylodan increases when calcium is added 
incrementally above concentrations of 0.1 mM (left: Figure 5.5). By 1 mM Ca2+ the fluorescence has 
blue-shifted and increased to a modest extent (appendix: Figure 6.25). In contrast, no excimer formation 
is exhibited by A5-pyrene. Consequently, the labeled-Lys8 residue is inserting into the PS membrane, 
however, no oligomers form. These results are potentially significant in A5-induced toxicity; the Lys8 
residue of A5 is inserting into the PS membrane at calcium concentrations which are physiologically 
relevant. However, the concentration of PS within the model membrane far exceeds that exposed to the 
outer membrane leaflet in vivo. When the PS concentration is decreased, the calcium required to 
promote binding will increase – as is seen with PG (appendix: Figure 6.3, Figure 6.4). Testing of A5 
and its analogs with membranes which better approximate the complex lipid composition of human 
tissue would be required to establish whether the interaction remains; that it does is unlikely. 
A5-acrylodan on the PC membrane exhibits similar results, however, the fluorescence increases to a 
lesser degree – consequently, the lipopeptide does not bind the PC membrane as avidly. On 100% PC 
membranes, the formation of excimer with A5-pyrene does not occur, therefore, the lipopeptide is again 
binding in a monomeric form (data not shown). In contrast to PS, PC is a major phospholipid within 
eukaryotic membranes, and it is not highly confined to the inner leaflet; therefore, the association of 
the peptide with PC may be more relevant to toxicity, despite its decreased interaction. However, this 
would not explain the targeted muscle toxicity seen with these lipopeptides in humans. 
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5.4 Discussion 
Considering the recent findings of Taylor et al.84, it is unexpected that Kyn fluorescence increased at 
high calcium concentration on the PS membrane in the absence of NBD-dap fluorescence. The 
fluorophore on the Orn6 residue typically tracks the first of the two successive calcium-dependent 
transitions: on PG model membranes, below 0.1 mM Ca2+ the labeled-Orn6 fluorescence increases, and 
above 0.1 mM Ca2+ the Kyn residue begins to respond. As a PS membrane is used rather than a PG 
membrane, it could be expected that the calcium concentrations required to initiate the two transitions 
is shifted to a higher calcium concentration – instead, the Kyn residue alone is seen to insert. 
Consequently, with the lack of excimer formation, dap is binding as a monomer. Since the binding is 
relegated to calcium concentrations above physiological levels, it is unrelated to dap-induced toxicity. 
The most straightforward answer as to why the typical calcium-dependent transitions are not 
observed is that PS cannot emulate PG for dap. Although the lipids share a net charge, the structure of 
the head group and distribution of the charges is different. The net −1 charge of PS is composed of a 
positive and negative charge on the serine amino and carboxylic acid groups, respectively, and a second 
negative charge on the phosphate group. The net −1 charge of PG is derived from a single negative 
charge on the phosphate group. 
On the other hand, A5 and its analogs exhibit a pattern of fluorescence which better reflect the 
initiation of the typical calcium-dependent transitions. At calcium concentrations above 0.1 mM Ca2+ 
the acrylodan-labeled Lys8 fluorescence begins to increase; this is representative of the first transition, 
which coincides with the binding of the first calcium ion. The calcium required is higher than usual, 
however, this is expected due to the lack of PG. The second transition, which coincides with another 
calcium ion, is not observed; Trp fluorescence does not blue-shift, and acrylodan fluorescence does not 
self-quench. Consequently, with the lack of excimer formation, A5 is also observed to insert as a 
monomer. Therefore, PS cannot truly emulate PG for A5 either; however, since the expected order of 
binding is observed at lower calcium concentration, the interaction may be increased in comparison to 
dap. Overall, it is unlikely that PS mediates either dap- or A5-induced toxicity in humans. 
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Chapter 6 
Characterizing the reliance of daptomycin on peptidoglycan 
precursors 
6.1 Introduction 
Several action modes for dap have been proposed; among them, the dissipation of the membrane 
potential due to the interaction of dap with bacterial phospholipid membranes is best supported by 
experimental evidence. The successive steps required to accomplish this mechanism have been 
demonstrated using various fluorescence-based assays on model membranes.52,73,80,124 The steps include 
the calcium-dependent binding of dap to the membrane, the formation and translocation of oligomers, 
and the ultimate alignment of cross-leaflet oligomers to form the cation- and size-selective pore. The 
only molecule in the target membrane proven to be specifically required is PG.55 
The objective of this work is to investigate whether interactions between peptidoglycan precursors 
and dap are of importance in its action mode. Related calcium-dependent lipopeptide antibiotics, such 
as laspartomycin and amphomycin, have an analogous structure – a macrocycle and exocyclic peptide 
to which is attached a fatty acyl tail – and are known to inhibit peptidoglycan synthesis by sequestration 
of the peptidoglycan precursor undecaprenol.28,29,61 Other antibiotics are also known to require 
peptidoglycan precursor ‘targeting molecules’, which mediate association with bacterial membranes. 
This includes the structurally unrelated lantibiotic nisin.38 Nisin is a pore-forming antibiotic which 
requires lipid II for efficient membrane association and permeabilization. Uncovering the requirement 
of a targeting molecule for dap, other than the PG, would be a large deviation from its known 
mechanism of action.  
The investigation into the importance of peptidoglycan precursors in dap’s antibacterial activity was 
carried out using MIC tests on B. subtilis L-forms. The MIC tests incorporated two antibiotics: one 
being dap, and the other to up- or down-regulate the abundance of a specific peptidoglycan precursor. 
If dap requires a specific precursor, its activity should increase or decrease accordingly. L-forms are 
essential as the test organism because they are capable of growth in the absence of a fully functional 
peptidoglycan layer; this allows them to survive the antibiotics which interact with peptidoglycan 
synthesis. Understanding the reliance of dap on cellular binding sites, may result in lipopeptides with 
improved activity on dap-resistant bacteria and modifications to the established mechanism of action. 
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Figure 6.1: Schematic of peptidoglycan synthesis, and the antibiotics which inhibit it at different stages of 
production. By inhibiting different stages, the abundance of precursors will increase or decrease; this can 
then be tested for its effect on dap activity.  
To up- or down-regulate the abundance of the peptidoglycan precursors, a variety of antibiotics can 
be used. Selection was made by choosing those which inhibit peptidoglycan synthesis at different stages 
(Figure 6.1). The list of chosen antibiotics, and the reasoning in regards to its effect on dap is below, 
for an overview see Table 6.1.  
1. Fosfomycin and cycloserine inhibit steps in the synthesis of the intracellular sugar and 
peptide precursors of peptidoglycan.21,24,26 These precursors are directly used for the 
production of lipid I and II, therefore their concentration will be reduced. Both lipid I and II 
in turn use the lipid carrier undecaprenol. Inhibited production of these precursors will leave 
undecaprenol phosphate free in the membrane, possibly at increased levels. If dap binds to 
undecaprenol, no change or even an increase in activity should be seen. On the other hand, 
if dap binds to lipid I or lipid II, a decrease in activity should be seen 
2. Vancomycin sequesters the D-alanyl-D-alanine dipeptide on lipid II.30 This should block any 
direct binding to lipid II; if dap binds to lipid II, a decrease in activity should be seen. 
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3. Moenomycin will block the transfer of lipid II to a growing strand of peptidoglycan.135 This 
will increase the amount of free lipid II. If dap binds to lipid II, the activity could increase. 
4. Laspartomycin sequesters undecaprenol.29 This blocks direct binding to undecaprenol, and 
reduces all upstream peptidoglycan precursors. If dap binds to undecaprenol, a decrease in 
activity should be seen.  
To validate the double antibiotic MIC assay, nisin can be used as a control. Nisin is a known lipid II 
binder, therefore its activity should be able up- or down-regulated when the abundance of lipid II is 
changed. In fact, the presence of vancomycin, another lipid II binder, has already been observed to 
partially block its activity.38 This test was carried out in the bacteria Micrococcus flavus, however the 
effect is expected to carry over to cell wall deficient B. subtilis L-form.  
Table 6.1: Antibiotics and their effect on peptidoglycan presurcors and dap activity. Dap activity changes 
assume it binds to the affected peptidoglycan precursor. UC indicates unchanged.  
 Precursor abundance or availability  
Antibiotic Lipid I Lipid II Undecaprenol Dap Activity 
Cycloserine ↓ ↓ UC (or ↑) ↓ (or ↑) 
Fosfomycin ↓ ↓ UC (or ↑) ↓ (or ↑) 
Vancomycin UC ↓ UC ↓ 
Moenomycin UC ↑ UC ↑ 
Laspartomycin UC UC ↓ ↓ 
     
6.2 Materials and Methods 
B. subtilis strain PDC 134 was generously provided by Centre for Bacterial Cell Biology, Institute for 
Cell and Molecular Biosciences (Newcastle upon Tyne, UK). Cycloserine, fosfomycin, laspartomycin, 
and ampicillin were purchased from BioShop Canada, Inc. (Burlington, ON, CAN). Vancomycin and 
nisin were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
6.2.1 Isolation of B. subtilis PDC 134 N-forms 
The B. subtilis PDC 134 strain was initially received as N-form cells within solid agar. A small piece 
of the original agar was isolated and streaked over an LB agar plate supplemented with 0.5% xylose. 
Two colonies were obtained after incubation overnight at 30 °C. A portion of one colony was 
subcultured into LB broth supplemented with both 0.5% xylose and 10 µg/mL of chloramphenicol 
  76 
(Table 6.2). Chloramphenicol selection was used to isolate PDC 134 from any possible contamination; 
this antibiotic can be used due to the inserted chloramphenicol resistance gene (cat) prior to the xylose-
dependent murE operon (ΩspoVD::cat Pxyl-murE; spoVD is a gene necessary for spore formation). 
Bacterial growth from the LB broth was then streaked across xylose supplemented LB agar. A single 
colony was isolated and subcultured back into broth. Growth will be genetically homogenous B. subtilis 
PDC 134 N-forms, and can be portioned into individual 150–200 µL stocks. Stocks contain 15–20% 
glycerol, and are kept at −80 °C. 
Table 6.2: MIC (µg/mL) of B. subtilis strains ATCC 1046 and PDC 134. PDC 134 includes both N- and L-
form. 
Antibiotic B. subtilis strain 
 ATCC 1046 PDC 134 (N-form) PDC 134 (L-form) 
Chloramphenicol 1–1.5 >20 >30 
    
6.2.2 Isolation of B. subtilis PDC 134 L-forms 
A xylose-free medium supplemented with MSM (Mg2+, 20 mM; maleic acid, 20 mM; sucrose, 500 
mM) at pH 7 was inoculated with the growth from an N-form stock grown beforehand in the presence 
of xylose and chloramphenicol (Figure 6.2A). The culture was incubated at 30 °C overnight. Upon 
microscopic investigation of the growth, rod-shaped cells were interspersed among small, spherical 
cells assumed to be L-forms (Figure 6.2B). The rod-shaped cells indicated either the transition to L-
form was not quantitative or contamination was involved. To rule out contamination, the growth was 
subcultured into chloramphenicol-supplemented MSM medium. The rod-shaped cells remained, 
making it likely they were untransformed N-forms of PDC 134 able to propagate without xylose. In an 
attempt to remove the rod-shaped cells, the growth was subcultured into media containing MSM and 
75 µg/mL of ampicillin. The media was highly turbid within 4 days, and microscopic investigation of 
the growth displayed only the spherical cells (Figure 6.2C). After testing, these cells showed osmotic 
lysis upon addition to water, an insensitivity to peptidoglycan-inhibiting antibiotics, and 
hypersensitivity to dap. As these are previously demonstrated qualities of B. subtilis L-forms, the 
spherical cells are believed to be L-forms. Frozen stocks were made in the same manner as the N-form 
stocks. 
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Figure 6.2: (A) One colony of PDC 134 N-forms grown in LB broth supplemented with 0.5% xylose, and 
20 µg/mL chloramphenicol. (B) PDC 134 N-forms subcultured in MSM LB broth (C) PDC 134 N- and L-
forms subcultured into MSM LB broth supplemented with 75 µg/mL ampicillin, giving a pure L-form 
culture. 
6.2.3 Determining the antibacterial activity of antibiotics 
The procedure for determining the minimum inhibitory concentration of the antibiotics has been 
described in a preceding chapter (see section 2.2.4) 
6.2.4 Determining the antibacterial activity of daptomycin in the presence of other 
antibiotics 
The antibiotic combinations were tested for antibacterial activity by broth dilution in a 96-well plate. 
Dap was added to wells at varying concentration above and below its MIC. The secondary antibiotic 
(which up- or down-regulates peptidoglycan precursors) was then added to the same wells at a fixed 
concentration above its MIC on N-form cells; this ensures the antibiotic is thoroughly affecting its 
antibacterial target and consequently changing the abundance of its associated peptidoglycan precursor. 
On the plate, the combinations were repeated 6 times, across all the concentrations. As a control, on the 
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same plate as the multiple antibiotic assay, an MIC with dap alone was completed. The concentrations 
of dap used are the same as the other multiple antibiotic assay. Each concentration is repeated 3 times 
on the plate.  For all tests, the growth medium was MSM LB supplemented with 5 mM Ca2+. Each well 
was inoculated with PDC 134 L-forms and incubated at 30 °C for 3 days. Bacterial growth in each well 
was evaluated visually by turbidity. 
6.3 Results 
6.3.1 The difference in antibacterial activity between B. subtilis L-forms and N-forms 
The transition to L-form allows cells to propagate freely without peptidoglycan as long as they are 
osmotically stabilized by the growth medium. Propagation in the cell wall deficient state is known to 
dramatically lower the sensitivity of the cells to antibiotics which affect the synthesis of the cell wall; 
including those discussed in the introduction (section 6.1). To verify that these antibiotics, which will 
be used to up- or down-regulate peptidoglycan precursors do not kill the L-forms, their antibacterial 
activities were determined (Table 6.3). As expected, the antibiotics have vastly increased MICs. 
However, laspartomycin is an exception. That its MIC on the L-forms is high is unexpected. 
Laspartomycin blocks the production of lipid I and lipid II by sequestering undecaprenol; this should 
have no effect on the bacteria.29 This is an interesting result and should be evaluated with further tests. 
The MICs of the chosen antibiotics were also determined on PDC 134 N-forms. The N-form cells, 
unlike the L-forms, continue to rely on peptidoglycan to survive. The MIC establishes a concentration 
of antibiotic which effectively inhibits its respective antibacterial target in the bacteria. Inhibition of 
the antibiotic’s antibacterial target indicates the abundance of the peptidoglycan precursor associated 
with its mechanism of action has been effectively up- or down-regulated.  
In the multiple antibiotic MIC assays, concentrations above the N-form MIC value can then be used 
on the L-forms; the L-form cells themselves will not die due to their inherent insensitivity to these 
mechanisms of action, however, the abundance of a particular peptidoglycan precursor is ensured to be 
effectively regulated. The activity of dap can then be tested without the presence of the affected 
precursor. All N-form MICs were similar to the. B subtilis strain ATCC 1046, which does not transition 
to L-form. 
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Table 6.3: MIC (µg/mL) of various antibiotics on B. subtilis ATCC 1046 and PDC 134 L-forms and N-
forms. 
Antibiotic B. subtilis strain 
 ATCC 1046 PDC 134 (N-form) PDC 134 (L-form) 
Dapa 0.75 0.5–0.75 0.075 
Ampicillin 2.5–5 2.5–5 >125 
Cycloserine 80–120 80–120 >220 
Fosfomycin 80–120 80–120 >200 
Nisin 5–7 2.5–5 3.0 
Vancomycin 0.15–0.175 0.15–0.20 ≥10 
Laspartomycin 4 4 1.5 
a5 mM Ca2+    
6.3.2 The reliance of daptomycin and nisin on B. subtilis PDC 134 peptidoglycan 
precursors 
It quickly became apparent the original method of regulating peptidoglycan precursors with antibiotics 
would not be as straight forward as expected. This is due to the method in which the PDC 134 strain 
inhibits its peptidoglycan synthesis to transition from N-form to L-form. PDC 134 has a xylose-
dependent promoter upstream of the murE operon, whose genes products are enzymes required for the 
very early steps in peptidoglycan synthesis. Consequently, in the L-form bacteria little or no 
peptidoglycan precursors are being synthesized when under normal growth conditions (xylose is absent 
from the growth medium). Due to this, the MIC of dap alone on the L-forms is analogous to dap in the 
presence of an early peptidoglycan synthesis inhibitor such as cycloserine or fosfomycin – which would 
have down-regulated lipid I and lipid II, and left undecaprenol free in the membrane. 
When the activity of dap was tested alone on the L-form bacteria under normal growth conditions, 
its activity increased 10-fold (0.075 µg/mL vs 0.75 µg/mL). Since the L-forms lack lipid I and lipid II, 
this demonstrates that interaction with those peptidoglycan precursors is not fundamental to dap’s 
mechanism of action. As a control against low background production of peptidoglycan precursors by 
the L-forms, the activity of dap in the presence of cycloserine was determined (Table 6.4). The addition 
of cycloserine would down-regulate any potentially remaining lipid I and lipid II production. The 
results determined that the presence of cycloserine has no change on the MIC of dap. This corroborates 
that the presence of the precursors is not fundamental to dap activity. 
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Table 6.4: MIC (µg/mL) of dap in the prescence of peptidoglycan precursor modulating antibiotics and 5 
mM calcium, on B. subtilis PDC 134 L-forms. Media used is MSM and LB. 
 Antibiotic Concentration  MIC 
Secondary Antibiotic Secondary Dap  Combination Dap Control 
Cycloserine 200 0–0.175  0.075 0.075 
      
Despite not being fundamental to activity, the lipid I or lipid II precursor could mediate increased 
membrane binding and activity, such as in the case of lipid II and nisin. Dap’s activity must therefore 
be tested in their presence. The biosynthesis of the peptidoglycan precursors was up-regulated through 
the use of xylose. Normally, introduction of xylose into the growth medium permits transition to the 
N-form, as peptidoglycan is freely produced. For that reason, the growth medium was additionally 
supplemented with ampicillin. Ampicillin will allow for synthesis of lipid I and lipid II, but block 
peptidoglycan cross-linking and consequently inhibit full reversion to a walled state. L-forms grown 
on this medium did not revert, as determined by microscopy. However, there are potential 
complications. Research with E. coli has shown an unexpected decrease in lipid I and lipid II with use 
of penicillin; this was in contrast to use of moenomycin, which increased the peptidoglycan 
precursors.136 The concentrations used by the authors were 641 µg/mL and 500 µg/mL, respectively. 
The β-lactam concentration used by the authors is a nearly 6.5-fold increase in concentration compared 
to the media used here with B. subtilis. Furthermore, in contrast to E. coli, the B. subtilis L-forms are 
not being lysed over the experiment timescale. The differences in bacterial species, and antibiotic 
concentration, bring into question the significance of these findings to this research. Ultimately, the 
results show dap’s activity is unchanged in the presence of supposedly increased lipid I and lipid II 
concentrations (Table 6.5). Dap is therefore unlikely to interact with these precursors in any way.  
Table 6.5: MIC (µg/mL) of dap on B. subtilis PDC 134 L-forms, in the prescence of media with differing 
composition, but always supplemented with 5 mM Ca2+. The media utilized is composed of MSM, and LB 
or MSM, Amp (100 µg/mL), 0.5% xylose, and LB.  
Antibiotic Growth medium 
 MSM media Amp, Xylose, MSM media 
Dap 0.075 0.075 
   
In the opposite situation to lipid I and lipid II, is the lipid carrier undecaprenol phosphate. 
Undecaprenol phosphate is not synthesized by gene products within the murE operon, therefore it 
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remains in the L-form membrane. Moreover, it is entirely free in the membrane under xylose-free 
conditions as no lipid I or II is being transferred to the carrier. If dap, like its laspartomycin-like 
lipopeptide counterparts, binds to this precursor a portion of the initial 10-fold increase in dap activity 
on L-forms could be due to the unrestricted access of dap to undecaprenol. To test this, laspartomycin 
was to be used – it binds to undecaprenol and would consequently block the binding of dap. However, 
unexpectedly, the initial MIC tests using laspartomycin with the L-forms showed an increased MIC 
compared to the N-forms (1.5 µg/mL vs 4 µg/mL). The L-forms are capable of peptidoglycan-free 
growth, therefore, the sequestration of undecaprenol should not kill the bacteria.29 Unfortunately, due 
to this the reliance of dap upon undecaprenol was not tested. However, that the L-forms die to 
laspartomycin is intriguing and should be followed up with other studies.  
In order to validate the tests done with dap and the L-forms under xylose-free and peptidoglycan 
precursor synthesizing conditions (xylose, ampicillin), nisin was used as a control. However, initial 
tests show that nisin, despite its known lipid II binding mechanism, may not be a useful control within 
this experimental set up. The MIC assay of nisin on PDC 134 N-forms and L-forms give results which 
are comparable to each other (2.5-5 µg/mL vs 3 µg/mL). L-forms lack lipid II, therefore the activity of 
nisin should be significantly decreased as it cannot efficiently initiate pore formation. Nisin can produce 
lipid II-independent pores but it has only been shown on model membranes and required 1,000-fold 
increased antibiotic concentration.137 A separate group, Wolf et al.138, encountered the same problem 
with nisin on PDC 134 L-forms. They proposed that nisin may be binding to a secondary target 
molecule; they pointed to a precursor of wall teichoic acid biosynthesis, which is flipped to the outer 
membrane using undecaprenol and has recently been shown to bind nisin.138,139 However, this is 
inadequate as its synthesis requires the enzymes within the suppressed murE operon.139 
Nevertheless, when nisin is used under precursor synthesizing conditions (xylose, ampicillin), the 
expected result is seen (Table 6.6). Attempting to up-regulate lipid II caused a decrease in nisin’s 
activity; however, the increase in activity is not large, which does not bode well for the sensitivity of 
the assay. Despite the success in this assay, that nisin’s activity is not inhibited under conditions which 
should have no production of its target molecule, lipid II, render it an invalid control for the assays 
overall. 
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Table 6.6: MIC (µg/mL) of nisin on B. subtilis PDC 134 L-forms, in the prescence of media with differing 
composition. The media utilized is composed of MSM, and LB or MSM, Amp (100 µg/mL), 0.5% xylose, 
and LB.  
Antibiotic Growth medium 
 MSM LB Amp, Xylose, MSM LB 
Nisin 3.0 2.5 
6.4 Discussion 
The multiple antibiotic MIC assay on L-forms resulted in some potentially promising results for the 
reliance of dap on lipid I and lipid II precursors; however, the control needed to validate them does not 
function as expected. Nisin’s activity is not inhibited under conditions which should have no production 
of its target molecule, lipid II. Consequently, no conclusions from the data can be made. Whether the 
assay could be recovered with the choice of a different control antibiotic is uncertain. 
Perhaps the most significant result from the attempts at the assay is the death of the L-forms to 
laspartomycin. No known mechanism of action accounts for this effect. First, the functionally-related 
lipopeptides such as amphomycin should be attempted. This will distinguish whether the effect occurs 
only by laspartomycin, or all its related antibiotics.  
Ultimately, the dap’s reliance on peptidoglycan precursors can be answered by a recent paper from 
Kleijn et al. (2016)29. The research group performed a multitude of tests to characterize the mechanism 
of action of laspartomycin and used dap as the comparator; below are is a brief overview of their results 
for dap: 
1. Addition of dap to S. aureus does not cause accumulation of the cytoplasmic lipid II 
precursor UDP-MurNAc-pentapeptide. This indicates no inhibition of upstream 
peptidoglycan precursor synthesis is happening, such as sequestration of undecaprenol. 
2. A thin-layer chromatography (TLC) binding assay did not show stable complex formation 
when dap was incubated with undecaprenol phosphate or lipid II. 
3. Direct addition of purified lipid I, lipid II, UDP-MurNAc-pentapeptide, UDP-GlcNAc, or 
undecaprenol phosphate at high concentrations to antibacterial activity assays does not 
antagonize the activity of dap. 
Consequently, dap has been shown not to rely on peptidoglycan precursors for antibacterial affect. 
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6.5 Conclusion 
To conclude, the findings from the chapters will be briefly summarized. Chapter 2 details the 
characterization of an acyl-linked dimer of dap. The dimer was found to undergo a mechanism of action 
identical to that of dap on model membranes. However, on bacteria its antibacterial activity is reduced 
due to sequestration into the peptidoglycan layer; furthermore, the dimerization affects the activity in 
some secondary manner. Consequently, dimerization is not a suitable method for increasing dap’s 
activity. Future work with the dimer is unlikely due to the manner of its inactivation, however, research 
into the process of oligomerization remains important.  
Chapter 3 details the characterization of additional synthetic analogs of dap, including dap-E12-W13 
and dap-E12-Y13. The dap-E12-W13 analog is amongst the most active dap analogs characterized by 
research groups so far. The high antibacterial activity and simplified synthetic procedure make it a 
viable candidate for the role as the base scaffold in the generation of a combinatorial analog library. 
The dap-E12-Y13 analog’s antibacterial activity is low unless calcium concentration is significantly 
increased; the amino acids in positions 12 and 13 appear to affect dap’s calcium affinity. Future work 
involves establishing the process for the synthetic library and the characterization of additional analogs 
to further develop the structure-activity relationships of dap.  
Chapter 4 details the characterization of LPG-mediated dap resistance. Overall, the mechanism of 
resistance is reminiscent of CL-mediated resistance; LPG appears to inhibit the translocation of dap 
oligomers across the membrane. The inhibition of translocation may occur due to LPG stabilizing the 
membrane. This would arise from the electrostatic interaction of LPG with PG; however, the data is 
not sufficient for a comprehensive explanation. Future work includes the examination of membranes 
with a larger range of LPG concentrations. This would corroborate the findings found here and allow 
for more in-depth tests.  
Chapter 5 contains the investigation into the role of PS in dap-induced toxicity. Due to the lack of 
significant dap interaction with a PS-containing membrane at physiological calcium concentrations, PS 
is unlikely to be involved in toxicity. The need for future work is uncertain. Chapter 6 details the 
investigation into the reliance of dap’s antibacterial activity on peptidoglycan precursors. Due to 
complications with the experimental assay and control, no data was able to be validated. The 
complications resulted from the B. subtilis PDC 134 strain utilized. Future work with a modified assay 
or different experimental setup is warranted.  
  84 
Permissions 
Figure 1.14: Reprinted from Biochimica et Biophysica (BBA) – Biomembranes, 1838, Zhang, T., 
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selective pores in model membranes, 2425–2430, Copyright 2016, with permission from Elsevier. 
Figure 1.15: This research was originally published in The Journal of Biological Chemistry. Zhang, T., 
Muraih, J. K., Tishbi, N., Herskowitz, J., Victor, R. L., Silverman, J., Uwumarenogie, S., Taylor, S. D., 
Palmer, M., and Mintzer, E. Cardiolipin prevents membrane translocation and permeabilization by 
daptomycin. J. Biol. Chem. 2014; 289:11584-91. © the American Society for Biochemistry and 
Molecular Biology. 
Figure 1.16: This research was originally published in The Journal of Biological Chemistry. Zhang, T., 
Muraih, J. K., Tishbi, N., Herskowitz, J., Victor, R. L., Silverman, J., Uwumarenogie, S., Taylor, S. D., 
Palmer, M., and Mintzer, E. Cardiolipin prevents membrane translocation and permeabilization by 
daptomycin. J. Biol. Chem. 2014; 289:11584-91. © the American Society for Biochemistry and 
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Appendix A 
Raw fluorescence figures 
 
Figure 6.3: Fluorescence spectrum of dap in the presence of 50:50 PC:PG liposomes and increasing Ca2+ 
concentration (mM) at 37 °C. Legend: Lip refers to liposomes, Cont refers to control.  
 
Figure 6.4: Fluorescence spectrum of dap in the presence of 70:30 PC:PG liposomes and increasing Ca2+ 
concentration (mM) at 37 °C. Legend: Lip refers to liposomes, Cont refers to control.  
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Figure 6.5: Fluorescence spectrum of solid-phase synthesis dap in the presence of 50:50 PC:PG liposomes 
and increasing Ca2+ concentration (mM) at 37 °C. Legend: Lip refers to liposomes, Cont refers to control.  
 
Figure 6.6: Fluorescence spectrum of dap dimer in the presence of 70:30 PC:PG liposomes and increasing 
Ca2+ concentration (mM) at 37 °C. Legend: Lip refers to liposomes, Cont refers to control.  
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Figure 6.7: Fluorescence spectrum of dap-E12-Y13 in the presence of 50:50 PC:PG liposomes and 
increasing Ca2+ concentration (mM) at 37 °C. Legend: Lip refers to liposomes, Cont refers to control. 
 
Figure 6.8: Fluorescence spectrum of dap-E12-Y13-pyrene in the presence of 50:50 PC:PG liposomes and 
increasing Ca2+ concentration (mM) at 37 °C. Legend: Lip refers to liposomes, Cont refers to control.  
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Figure 6.9: Fluorescence spectrum of dap-perylene in the presence of 70:30 PC:PG liposomes and 
increasing Ca2+ concentration (mM) at 37 °C. Legend: Lip refers to liposomes, Cont refers to control. 
 
Figure 6.10: Fluorescence spectrum of A5 in the presence of 50:50 PC:PG liposomes and increasing Ca2+ 
concentration (mM) at 37 °C. Legend: Lip refers to liposomes, Cont refers to control.  
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Figure 6.11: Fluorescence spectrum of A5-acrylodan in the presence of 50:50 PC:PG liposomes and 
increasing Ca2+ concentration (mM) at 37 °C. Legend: Lip refers to liposomes, Cont refers to control. 
 
Figure 6.12: Fluorescence spectrum of A5-pyrene in the presence of 70:30 PC:PG liposomes and increasing 
Ca2+ concentration (mM) at 37 °C. Legend: Lip refers to liposomes, Cont refers to control.  
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Figure 6.13: Fluorescence spectrum of dap in the presence of 55:30:15 PC:PG:LPG liposomes and 
increasing Ca2+ concentration (mM) under ambient conditions (~25 °C).  Performed on the day of 
membrane production. Legend: Lip refers to liposomes, Cont refers to control.  
 
Figure 6.14: Fluorescence spectrum of A5 in the presence of 55:30:15 PC:PG:LPG liposomes and 
increasing Ca2+ concentration (mM) under ambient conditions (~25 °C). Performed on the day of 
membrane production. Legend: Lip refers to liposomes, Cont refers to control. 
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Figure 6.15: Fluorescence spectrum of A5-acrylodan in the presence of 55:30:15 PC:PG:LPG liposomes 
and increasing Ca2+ concentration (mM) under ambient conditions (~25 °C). Performed on the day of 
membrane production. Legend: Lip refers to liposomes, Cont refers to control. 
 
Figure 6.16: Fluorescence spectrum of A5-pyrene in the presence of 55:30:15 PC:PG:LPG liposomes and 
increasing Ca2+ concentration (mM) under ambient conditions (~25 °C).  Performed on the day of 
membrane production. Legend: Lip refers to liposomes, Cont refers to control.  
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Figure 6.17: Fluorescence spectrum of dap in the presence of 70:30 PC:LPG liposomes and increasing Ca2+ 
concentration (mM) at 37 °C. Performed on the day of membrane production. Legend: Lip refers to 
liposomes, Cont refers to control. 
 
Figure 6.18: Fluorescence spectrum of A5 in the presence of 70:30 PC:LPG liposomes and increasing Ca2+ 
concentration (mM) at 37 °C. Performed on the day of membrane production. Legend: Lip refers to 
liposomes, Cont refers to control. 
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Figure 6.19: Fluorescence spectrum of A5-acrylodan in the presence of 70:30 PC:LPG liposomes and 
increasing Ca2+ concentration (mM) at 37 °C. Performed on the day of membrane production. Legend: Lip 
refers to liposomes, Cont refers to control. 
 
Figure 6.20: Fluorescence spectrum of A5-pyrene in the presence of 70:30 PC:LPG liposomes and 
increasing Ca2+ concentration (mM) at 37 °C. Performed on the day of membrane production. Legend: Lip 
refers to liposomes, Cont refers to control. 
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Figure 6.21: Fluorescence spectrum of dap in the presence of 70:30 PC:PS liposomes and increasing Ca2+ 
concentration (mM) at 37 °C. Legend: Lip refers to liposomes, Cont refers to control. 
 
Figure 6.22: Fluorescence spectrum of NBD-dap in the presence of 70:30 PC:PS liposomes and increasing 
Ca2+ concentration (mM) at 37 °C. Legend: Lip refers to liposomes, Cont refers to control.  
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Figure 6.23: Fluorescence spectrum of dap-perylene in the presence of 70:30 PC:PS liposomes  and 
increasing Ca2+ concentration (mM) at 37 °C. Legend: Lip refers to liposomes, Cont refers to control. 
 
Figure 6.24: Fluorescence spectrum of A5 in the presence of 70:30 PC:PS liposomes and increasing Ca2+ 
concentration (mM) at 37 °C. Legend: Lip refers to liposomes, Cont refers to control. 
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Figure 6.25: Fluorescence spectrum of A5-acrylodan in the presence of 70:30 PC:PS liposomes and 
increasing Ca2+ concentration (mM) at 37 °C. Legend: Lip refers to liposomes, Cont refers to control. 
 
Figure 6.26: Fluorescence spectrum of A5-pyrene in the presence of 70:30 PC:PS liposomes and increasing 
Ca2+ concentration (mM) at 37 °C. Legend: Lip refers to liposomes, Cont refers to control. 
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Figure 6.27: Fluorescence spectrum of dap in the presence of 100% PC liposomes and increasing Ca2+ 
concentration (mM) at 37 °C. Legend: Lip refers to liposomes, Cont refers to control. 
 
Figure 6.28: Fluorescence spectrum of dap-E12-W13 in the presence of 100% PC liposomes and increasing 
Ca2+ concentration (mM) at 37 °C. Legend: Lip refers to liposomes, Cont refers to control. 
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Figure 6.29: Fluorescence spectrum of dap-E12-Y13 in the presence of 100% PC liposomes and increasing 
Ca2+ concentration (mM) at 37 °C. Legend: Lip refers to liposomes, Cont refers to control. 
 
Figure 6.30: Fluorescence spectrum of A5 in the presence of 100% PC liposomes and increasing Ca2+ 
concentration (mM) at 37 °C. Legend: Lip refers to liposomes, Cont refers to control. 
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Figure 6.31: Fluorescence spectrum of A5-acrylodan in the presence of 100% PC liposomes and increasing 
Ca2+ concentration (mM) at 37 °C. Legend: Lip refers to liposomes, Cont refers to control. 
 
Figure 6.32: Fluorescence spectrum of dap in the presence B. subtilis PDC 134 L-forms (OD600 = 0.8) and 
increasing Ca2+ concentration (mM) at 30 °C. Legend: Lip refers to liposomes, Cont refers to control. 
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Figure 6.33: Fluorescence spectrum of dap dimer in the presence B. subtilis PDC 134 L-forms (OD600 = 0.8) 
and increasing Ca2+ concentration (mM) at 30 °C.Legend: Lip refers to liposomes, Cont refers to control. 
 
Figure 6.34: Fluorescence spectrum of NBD-dap in the presence B. subtilis PDC 134 L-forms (OD600 = 0.8) 
and increasing Ca2+ concentration (mM) at 30 °C. Legend: Lip refers to liposomes, Cont refers to control. 
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Figure 6.35: Fluorescence spectrum of dap-perylene in the presence B. subtilis PDC 134 L-forms (OD600 = 
0.8) and increasing Ca2+ concentration (mM) at 30 °C. Legend: Lip refers to liposomes, Cont refers to 
control. 
 
Figure 6.36: Fluorescence spectrum of dap in the presence B. subtilis PDC 134 N-forms (OD600 = 0.4) and 
increasing Ca2+ concentration (mM) at 30 °C. Legend: Lip refers to liposomes, Cont refers to control. 
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Figure 6.37: Fluorescence spectrum of A5 in the presence 1% BLES and increasing Ca2+ concentration 
(mM) at 30 °C. Legend: Lip refers to liposomes, Cont refers to control. 
 
Figure 6.38: Fluorescence spectrum of dap in the presence of 1% BLES and increasing Ca2+ concentration 
(mM) at 30 °C. Legend: Lip refers to liposomes, Cont refers to control. 
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Figure 6.39: Fluorescence spectrum of dap-E12-W13 in the presence of 1% BLES and increasing Ca2+ 
concentration (mM) at 30 °C. Legend: Lip refers to liposomes, Cont refers to control. 
 
Figure 6.40: Liposome permeabilization test controls for the multiple lipopeptide analogs at 25 °C. 
Liposome controls were both at the start of the experiment and at the end. Ca2+ and CCCP alone raised 
the baseline a negligable amount. Fluorescence is normalized to the higest signal after Triton-X additon at 
300s. Legend: Lip refers to liposomes 
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Figure 6.41: Liposome permeabilization test using dap in the presence of 5 mM Ca2+ and 5 nM CCCP at 
25 °C. Controls include lipopeptide alone or in the presence of either Ca2+ or CCCP. The excitation and 
emission wavelengths are 460 nm and 510 nm, respectively. Fluorescence is normalized to the highest signal 
after Triton-X addition at 300s. Legend: Lip refers to liposomes, Cont refers to control. 
 
Figure 6.42 Liposome permeabilization test using dap-E12-W13 in the presence of 5 mM Ca2+ and 5 nM 
CCCP at 25 °C. Controls include lipopeptide alone or in the presence of either Ca2+ or CCCP. The 
excitation and emission wavelengths are 460 nm and 510 nm, respectively. Fluorescence is normalized to 
the highest signal after Triton-X addition at 300s. Legend: Lip refers to liposomes, Cont refers to control. 
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Figure 6.43 Liposome permeabilization test using dap-E12-Y13 in the presence of 5 (or 100) mM Ca2+ and 
5 nM CCCP at 25 °C. Controls include lipopeptide alone or in the presence of either Ca2+ or CCCP. The 
excitation and emission wavelengths are 460 nm and 510 nm, respectively. Fluorescence is normalized to 
the highest signal after Triton-X addition at 300s. Legend: Lip refers to liposomes, Cont refers to control. 
 
Figure 6.44 Liposome permeabilization test using A5 in the presence of 5 mM Ca2+ and 5 nM CCCP at 25 
°C. Controls include lipopeptide alone or in the presence of either Ca2+ or CCCP. The excitation and 
emission wavelengths are 460 nm and 510 nm, respectively. Fluorescence is normalized to the highest signal 
after Triton-X addition at 300s. Legend: Lip refers to liposomes, Cont refers to control. 
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Figure 6.45 Liposome permeabilization test using A5-Pyrene in the presence of 5 mM Ca2+ and 5 nM CCCP 
at 25 °C. Controls include lipopeptide alone or in the presence of either Ca2+ or CCCP. The excitation and 
emission wavelengths are 460 nm and 510 nm, respectively. Fluorescence is not normalized due to the 
highest initial signal of A5-pyrene. Triton-X addition is continued at 300s. Legend: Lip refers to liposomes, 
Cont refers to control. 
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